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CHAPTER-I 
INTRODUCTION 
ORAL CONTROLLED DRUG DELIVERY SYSTEMS 
Oral ingestion has long been the most convenient and commonly employed 
route of drug delivery. Indeed, for controlled release systems the oral route of 
administration has received attention with respect to research on physiological and drug 
constraints as well as design and testing of product. This is because there is more 
flexibility in dosage form design for oral route than that of parenteral route. Drug 
delivery technologies are the formulation technologies that modify drug release profile, 
absorption, distribution and elimination for the benefit of improving product efficacy 
and safety, as well as patient convenience and compliance (Brahmankar.D.M., 
Jaiswal.S.B., 2007).  
Routes of administration  
1. Enteral. 
2. Topical. 
3. Parenteral. 
1. Enteral drug delivery: 
It includes peroral i.e. 
 Gastro-intestinal 
 Sub-lingual 
 Rectal 
2. Topical drug delivery: 
It includes skin, eyes or other membranes. 
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 Intranasal 
 Inhalational 
 Intravaginal 
 Transdermal 
3. Parenteral drug delivery: 
It includes all routes of administration through or under one or more layers of skin. 
 Intramuscular  
 Subcutaneous 
 Intravenous 
 
The most preferred route of drug administration for systemic delivery of drugs is 
orally (Chien, Y.W., 1982). More than 50% of drug delivery systems available in the 
market are oral drug delivery systems. These systems have the obvious advantages of 
case of administration and patient acceptance. Several oral drug delivery technologies 
have come and gone, and new systems still emerge even today. 
 One would always like to have ideal drug delivery systems that will possess 
two main properties (Lingaraj, et al, 2010), 
1. It will be a single dose for the whole duration of treatment,  
2. It will deliver the active drug directly at the site of action. 
 
The Challenge: 
Most of the marketed products currently available are immediate release 
products. To achieve and maintain the concentration of an administered drug within 
therapeutically effective range (Vyas.S.P.,Khar R K., 2002. Chien, Y.W., 1982. 
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Brahmankar.D.M., Jaiswal.S.B., 2007)  it is often necessary to take drug dosage several 
times and this result in a fluctuating drug level in plasma. 
  The Controlled Release:
 
 Controlled drug delivery is one which delivers the drug at a predetermined rate, 
for locally or systemically, for a specified period of time. 
 Continuous oral delivery of drugs at predictable & reproducible kinetics for 
predetermined period throughout the course of GIT. 
There are many benefits offered by controlled drug delivery systems (Chien, 
Y.W., 1982). For example, sustained release technologies allow prolonged delivery of a 
therapeutic dose, thus reducing the number of times that a patient needs to take their 
medication while maintaining a steady state of drug in the bloodstream, and time-
delayed release introduces a lag time before dose release, providing pulsatile delivery of 
drug to specific sites, such as the colon, or at a specific time. Temporal control of drug 
release has particular advantages in the treatment of disorders that demonstrate a 
circadian pattern, such as cardiovascular disorders, asthma, anxiety and 
hypercholesterolemia. In such cases, the development of controlled-release 
formulations that deliver the payload at an optimal time can greatly enhance the 
therapeutic effects of the drug and reduce the dose required. 
 
Potential methods that can be used to retard drug release are: 
 
1. Capsules of polymeric material filled with a solid or liquid drug or with a 
suspension of drug, in which drug release is controlled by diffusion through the 
capsule wall. 
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2. A heterogeneous dispersion of drug particles in a solid matrix which can be either 
biodegradable or non-biodegradable, and drug release is controlled by diffusion 
through or erosion of the matrix, or both. 
 
3. A laminate of agent and polymeric material made by coating a film of 
biodegradable material with solid drug and then by forming the filminto a sealed 
"Sandwich" or "Jelly roll" in which drug release is controlled by diffusion, 
erosion, or both(Robinson J.R. and Lee V.H.L., 1987.). 
 
 
4. Liquid-liquid encapsulation of the drug in a viscous solution of polymer, in which 
drug release is controlled by slow diffusion through dilution of the media (Zhao 
W.Q., Pu B.Y. and Hartland S., 1993). 
 
5. Pumps that either mechanically or chemically (osmotic pressure) provide drug in a 
controlled manner (Prabakaran D., et al., 2004, Li X., Pan W., Nie S. and Wu 
L., 2004. Verma R.K. and Garg S., 2004). 
 
6. Microparticles that have an apparent density lower than that of gastric juice. Thus, 
the final product float on gastric juice for an extended period while slowly 
releasing the drug (Streubel A., et al., 2002, EL-Kamel A.H., 2001).  
 
7. Drug-containing bio adhesive polymer that adheres to the mucin coating of the 
gastrointestinal tract (GIT) and retained on the surface epithelium to extend GI 
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transit time of the drug. Drug is released at a constant rate from the bio adhesive 
polymer for subsequent absorption (Kriwet B et al., 1998)  
 
8. Chemical bonding of drug to a polymer backbone by pendent amide or ester 
linkage, in which drug release is controlled by hydrolysis (Hoste K., et al 2004)   
 
ORAL CONTROLLED RELEASE FORMULATIONS: 
Oral route has been the commonly selected and most convenient for the drug 
delivery. (Vyas.S.P., Khar R K., 2002) Oral route of administration has more attention 
in the pharmaceutical field because of the more flexibility in the designing of dosage 
form than routes drug delivery.  
Most of the oral controlled drug delivery systems rely on diffusion, dissolution 
or combination of both mechanisms, to release the drug in a controlled manner to the 
Gastrointestinal Tract (GIT).  
Novel oral drug delivery systems are broadly classified in to two categories as 
they may controlled release dosage forms as well as targeting dosage forms. General 
controlled manner in the GIT for systemic uptake and no particular area of GIT 
specified. In contrast, targeted preparations are releasing the drug in a specified area or 
tissue of the GIT (e.g. colon specific drug delivery systems). 
Targeting systems are either releasing drug in controlled manner or in one burst 
at the specific area (Vyas, S.P., Khar, and R.K). The goal of a targeted oral drug 
delivery system (TODDS) is to achieve better therapeutics success compared to 
conventional dosage form. This can be achieved by improving the pharmacokinetic 
profile, patient convenience and compliance in therapy, some of the advantages of 
TODDS are: 
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 Reduced dosing frequency 
 Better patient convenience and compliance 
 Reduced GI side effects and other toxic effects. 
 Less fluctuating plasma drug level 
 More uniform drug effect 
 Less total dose 
 Better stability of the drug. 
On the other hand TODDS suffer from a number of potential disadvantages: 
o Higher cost 
o Relatively poor in vitro-in vivo correlation 
o Possible dose dumping  
o Reduced potential for dose change or withdrawal in the event of toxicity 
Targeting of drugs through oral route involves control of time of release or 
location of release. On the basis of environmental, anatomical and physiological factors 
these drug delivery system can be classified with respect to target site as follows: 
 Systems targeted to stomach/duodenum 
 Systems targeted to small intestine 
 Systems targeted to large intestine/colon 
 Systems targeted to lymphatic. 
Oral Diffusion-Controlled Systems:
     
 
The basic concepts of oral controlled release dosage forms can be defined based 
on release-profile characteristic or the underlying release- controlling mechanism 
(Xiaoling Li, Bhaskara R. Jasti., 2005). Two distinct drug release profiles, extended and 
delayed release, are achievable, and they can be used in various combinations to 
 Chapter-I                                                                                        INTRODUCTION  
 
Madurai Medical College Page 7 
 
provide the desired release rate. Three delivery systems dominate today’s market of oral 
CR products: 
 Matrix systems. 
 reservoir  systems and 
 osmotic systems. 
             Release mechanisms from these dosage forms, diffusion plays a key role in 
both matrix and reservoir systems, whereas osmotic pressure is the predominant 
mechanism of drug release from osmotic systems and could also play a role in a 
reservoir system. 
Matrix systems 
A matrix system consists of active and inactive ingredients that are 
homogeneously mixed in the dosage form. Matrix systems divide into two categories, 
based on rate-controlling materials. 
 Hydrophobic matrix systems 
 Hydrophilic matrix systems  
Hydrophobic matrix systems: 
This is the only system where use of a polymer is not essential to provide 
controlled drug release, although insoluble polymers have been used. As the term 
suggests, the primary rate-controlling components of a hydrophobic matrix are water 
insoluble in nature. These ingredients include waxes, glycerides, fatty acids, and 
polymeric materials such as ethyl cellulose and methacrylate copolymers. To modulate 
drug release, it is necessary to incorporate soluble ingredients such as lactose into the 
formulation. 
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The presence of insoluble ingredients in the formulations helps to maintain the 
physical dimension of a hydrophobic matrix during drug release. Diffusion of the active 
form from the system is the release mechanism. Very often, pores form within a 
hydrophobic matrix as a result of the release of the active ingredient. Hydrophobic 
matrix systems generally are not suitable for insoluble drugs because the concentration 
gradient is too low to render drug release. 
 
Hydrophilic matrix systems  
The primary rate-controlling ingredients of a hydrophilic matrix are polymers 
that would swell on contact with the aqueous solution and form a gel layer on the 
surface of the system. 
Drugs release from hydrophilic matrices is by polymer dissolution (erosion) and 
diffusion of drug molecules across the gel layer have been identified as the rate-
controlling mechanisms.  
The model semi empirical “exponent equation” has been used widely to 
differentiate the contributions of both mechanisms: 
                                                       Qt =kt
n 
Where Qt is amount Q in time t, n is a diffusion exponent, and k is a kinetic constant. If 
diffusion dominates polymer erosion, the value of n would approach 0.5. On the other 
hand, for erosion-controlled formulations, n would approach the value of unity. Under 
an “anomalous” condition, the value of n falls in between 0.5 and 1 when both diffusion 
and erosion play roles.  
 For very soluble compounds, diffusion of drug molecules is the dominant 
mechanism of release, and the role of polymer erosion is limited in modulating drug 
release. Thus, developing a hydrophilic matrix for highly soluble drugs that requires 
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prolonged release (e.g., >12 h) can be challenging. On the other hand, release of less 
soluble drugs from hydrophilic matrices is expected to be slow because both polymer 
dissolution and drug diffusion play key roles (Xiaoling Li, Bhaskara R. Jasti., 2005):.  
 
Classification of oral controlled drug delivery system  
1. Continuous release system  
1. Dissolution controlled release system 
2. Diffusion controlled release system  
3. Diffusion and dissolution controlled release system.  
4. ion exchange resin drug complexes  
5. slow dissolving salt and complexes  
6. pH independent formulations. 
7. Osmotic pressure controlled systems 
8. Hydrodynamic pressure controlled systems.  
 
      2.    Delayed transit and continuous release systems  
1. Altered density system. 
2.   Mucoadhesive system. 
3. Size based systems. 
        3.    Delayed Release system  
1. Intestinal release system. 
2. Colonic release system. 
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Factors influencing the design and performance of controlled drug delivery system 
(Vyas.S.P.,Khar R K, 2002. Vyas, S.P., Khar, R.K.,  Xiaoling Li, Bhaskara R. Jasti., 
2005).  
 
a) Biopharmaceutic characteristic of the drug  
1. Molecular weight of the drug  
2. Aqueous solubility of the drug  
3. Apparent partition coefficient  
4. Drug Pka and ionization physiological pH  
5. Drug stability  
6. Mechanism and site of absorption  
7. Route of administration. 
b) Pharmacokinetic characteristic of the drug  
1. Absorption rate  
2. Elimination half life  
3. Rate of metabolism  
4. Dosage form index  
c) Pharmacodynamic characteristic of the drug  
1. Therapeutic range  
2. Therapeutic index  
3. Plasma–concentration–response relationship  
Advantages of controlled drug delivery systems:  
 
• Improved patient convenience and compliance  
• Reduction in fluctuation in steady state levels. 
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• Increased safety margin of high potency drugs. 
• Reduction in dose. 
• Reduction in health care cost.  
• Total dose is low. 
• Reduced GI side effects.  
•  Reduced dosing frequency.    
• Better patient acceptance and compliance.  
•  Less fluctuation at plasma drug levels.  
• More uniform drug effect  
•  Improved efficacy/safety ratio.  
• Dose dumping.   
• Reduced potential for accurate dose adjustment. 
• Need of additional patient education. 
Disadvantages of controlled drug delivery systems  
 
 Decreased systemic availability. 
 Poor invitro-invivo correlations. 
 Chances of dose dumping. 
 Dose withdrawal is not possible. 
 Higher cost of formulation. 
 
Microencapsulation Techniques 
Coacervation: 
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  It is the earliest process used to make an encapsulated product. This process 
utilized the interaction of two oppositely charged polyelectrolyte in water to form a 
polymer–rich coating solution called a coacervate (Leon Lachman, Lieberman H A, 
Kanig J L). Both water soluble and insoluble drugs can be microencapsulated. 
 
Interfacial Polymerization:  
It involves dispersing the organic phase containing drug particles into the 
aqueous phase containing monomers, whereby monomers react at liquid / liquid 
interface to form a capsule wall (Ji J., Childs R.F. and Mehta M., 2001). Drugs best 
encapsulated with this method are low-melting solid or poorly soluble organic liquids. 
 
Electrostatic Method: 
 It is useful when the coating material and drug to be encapsulated are both 
aerosols and oppositely charged (Zaho Y.,et al 2005). The drug and coating material are 
atomized resulting in the formation of microcapsules, which are then cooled and 
collected by an appropriate aerosol collecting system. 
 
Precipitation Process: 
 It covers many techniques. For examples, gelation of calcium alginate with 
calcium salt solution, and precipitate of a polymer around the drug being encapsulated 
by adding antisolvent (Tu L.S., Dehghani F. and Foster N.R., 2002). 
Hot Melt Techniques: 
It involves mechanical drop formation at an elevated temperature followed by a 
cooling step. The polymers used in this technique have low melt viscosities at 
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reasonable operating Temperature and can be readily sprayed. Drugs to be encapsulated 
by this method must be thermally stable (Souto E.B et al., 2005).  
 
Salting Out Method:  
It involves the addition of salt to an aqueousPolymer solution thereby separating 
the polymer from solution. One concern with this method is the possibility to 
incorporate a relatively high concentration of salt into the capsule wall (Konan Y.N., 
Gurny R. and Allémann E., 2002). 
 
Solvent Evaporation Techniques: 
  In this method drug and polymer are dissolved in a water immiscible volatile 
organic solvent and then dispersed into an aqueous solution to form an emulsion, the 
organic solvent is evaporated and solid microcapsule is formed (Freitas S., Merkle H.P. 
and Grander B., 2005). 
 
Air Suspension Method:  
In this method, the solid-particular core materials are dispersed in a supporting 
air stream and spray coating the suspended particles with a polymer solution (Rodriguez 
L.et al 2004). 
 
Multiorifice – Centrifuge: 
This process is mechanical in nature and use centrifugal forces to core material 
particles through polymer films formed across a hole in a spinning centrifuge(54), thus 
enveloping the core-material particles and forming microcapsules. The embryonic 
 Chapter-I                                                                                        INTRODUCTION  
 
Madurai Medical College Page 14 
 
microcapsules are hardened by collection in air or in a solution of a hardening agent 
(Leon Lachman, Lieberman H A, Kanig J L,). 
 
 
Pan–Coating Techniques:  
The micronized drug material is deposited onto various spherical substrates and 
coated with multiple layers of film-forming polymers in a coating pan (Pearnchob N 
and Bodmeier R., 2003). 
 
Spray Drying: 
  In this method the core material is dispersed into a coating solution or polymer 
melt and atomized the mixture into an air stream, which is usually heated, the solvent is 
removed, thus the polymers are collapsed around the particles (Bruschi M.L et al 2003). 
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CHAPTER-II 
GASTRO RETENTIVE DRUG DELIVERY SYSTEM  
  
Gastro retentive Drug Delivery System  
 
Gastroretentive dosage forms are drug delivery systems which remain in the 
stomach for an extended period of time and allow both spatial and temporal control of 
drug liberation. Basically gastroretentive systems swells following ingestion and is 
retained in the stomach for a number of hours, while it continuously releases the 
incorporated drug at a controlled rate to preferred absorption sites in the upper 
intestinal tract (Stanley Davies., 2005). Their application can be advantageous in the 
case of drugs absorbed mainly from the upper part of GIT or are unstable in the medium 
of distal intestine. 
 
 Gastrointestinal Tract 
 
 Anatomy of the gastrointestinal tract: 
 
The gastrointestinal tract is divided into three main regions namely: 
 Stomach.  
 Small intestine (Duodenum, Jejunum and Ileum).             
  Large intestine. 
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Figure 1 
 The GIT is a muscular tube, from the mouth to the anus, which functions to 
take in nutrients and eliminate waste by secretion, motility, digestion, absorption and 
excretion, which are known as physiological processes. The stomach is a J-shaped 
enlargement of the GIT which is divided into 4 anatomical regions: 
 cardia  
 fundus  
 body  
 antrum.  
The main function of the stomach is to store and mix food with gastric 
secretions before emptying its load (chyme) through the pyloric sphincter and into the 
small intestine at a controlled rate suitable for digestion and absorption. During empty 
state, the stomach occupies a volume of about 50 ml, but this may increase to as much 
as 1 litre when full. The walls of the GIT, from stomach to large intestine, have the 
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same basic arrangement of  tissues, the different layers, from outside to inside, 
comprising serosa, intermuscular plane, longitudinal muscle, submucosa, circular 
muscle, lamina propria, muscularis mucosae, and epithelium. In addition to longitudinal 
and circular muscle, the stomach has a third muscle layer known as the "oblique muscle 
layer", which is situated in the proximal stomach, branching over the fundus and higher 
regions of the gastric body. The different smooth muscle layers are responsible for 
performing the motor functions of the GIT, i.e. gastric emptying and intestinal transit.                                 
Basic gastrointestinal tract physiology 
The stomach is divided into 3 regions anatomically: fundus, body, and antrum 
pylorus. The proximal part is the fundus and the body acts as a reservoir for 
undigested material, whereas the antrum is the main site for mixing motions and acts as 
a pump for gastric emptying by propelling actions. Gastric emptying occurs during 
fasting as well as fed states but the pattern of motility is distinct in the 2 states. During 
the fasting state an interdigestive series of electrical events take place, which cycle 
through both stomach and intestine every 2 to 3 hours. This is called the interdigestive 
myloelectric cycle or migrating myloelectric cycle (MMC), which is divided into 
following 4 phases
 
are: 
 
 Phase I: This period lasts about 30 to 60 minutes with no contractions.  
 Phase II: This period consists of intermittent contractions that increase 
gradually in intensity as the phase progresses, and it lasts about 20 to 40 
minutes. Gastric discharge of fluid and very small particles begins later in this 
phase.  
 Phase III: This is a short period of intense distal and proximal gastric 
contractions (4-5 contractions per minute) lasting about 10 to 20 minutes these 
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P, Passive diffusion; C, Convective or aqueous channel transport; A, Active transport; 
F, Facilitated transport; I, Ion-pair transport; E, Entero-or pinocytocis; CM, Caveolin 
Mediated transport. 
Need for gastroretention  
• Drugs that are absorbed from the proximal part of the gastrointestinal tract 
(GIT). 
• Drugs that are less soluble or that degrade at the alkaline pH. 
•  Drugs that are absorbed due to variable gastric emptying time. 
•  Local or sustained drug delivery to the stomach and proximal small intestine to 
treat certain conditions (Brahmankar.D.M., Jaiswal.S.B.,). 
• Treatment of peptic ulcers caused by H.Pylori infections (Mona Semalty et al., 
2010).  
 Formulation considerations for GRDDS 
 It must be effective retention in the stomach to suit for the clinical demand.  
 It must be convenient for intake to facilitate patient compliance.  
 It must have sufficient drug loading capacity and control drug release profile.  
 It must have full degradation and evacuation of the system once the drug release 
is over.  
 It should not have effect on gastric motility including emptying pattern.  
 It should not have other local adverse effects (Vyas, S.P., Khar, R.K.,Targeted 
and controlled drug deliver,). 
 Certain types of drugs can benefit from using gastro retentive devices 
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 Drugs with a narrow absorption window.  
 Drugs acting locally in the stomach.  
 Drugs those are primarily absorbed in the stomach.  
 Drugs those are poorly soluble at an alkaline p
H
.  
 Drugs absorbed rapidly from the GI tract.  
 Drugs those degrade in the colon (Xiaoling Li, Bhaskara R. Jasti., 2005). 
 Drugs those are unsuitable for gastro retentive drug delivery systems 
 Drugs that have very limited acid solubility e.g. Phenytoin etc.  
 Drugs that suffer instability in the gastric environment e.g. Erythromycin etc.  
 Drugs intended for selective release in the colon e.g. 5- amino salicylic acid and 
corticosteroids etc. (European Pharmacopoeia 2009). 
Factors affecting gastric retention 
Various factors that affect the bioavailability of dosage form and efficacy of the gastro 
retentive system (Xiaoling Li, Bhaskara R. Jasti., 2005) are:        
 Density: Gastric retention time (GRT) is a function of buoyancy of dosage form 
that is dependent on the density.  
 Size: Dosage form units with a diameter of more than 7.5 mm are reported to 
have an increased GRT compared with those with a diameter of 9.9 mm.  
 Shape: Tetrahedron and ring shaped devices with a flexural modulus of 48 and 
22.5 kilo pounds per square inch (KSI) are reported to have better GRT 90% to 
100% retention at 24 hours compared with other shapes.  
 Single or Multiple unit formulation: Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to 
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failure of units, allow co-administration of units with different release profiles or 
containing incompatible substances and permit a larger margin of safety against 
dosage form failure compared with single unit dosage forms. 
 Fed or unfed state: Under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or the migrating myoelectric complex 
(MMC) that occurs every 1.5 to 2hrs. The MMC sweeps undigested material 
from the stomach and, if the timing of administration of the formulation 
coincides with that of the MMC, the GRT of the unit can be expected to be very 
short. However, in the fed state, MMC is delayed and GRT is considerably 
longer.  
 Nature of meal: Feeding of indigestible polymers or fatty acid salts can change 
the motility pattern of the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release.  
 Caloric content: GRT can be increased by 4 to 10 hours with a meal that is 
high in proteins and fats.  
 Frequency of feed: The GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC.  
 Gender: Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with 
their age and race matched female counterparts (4.6±1.2 hours), regardless of 
the weight, height and body surface).  
 Age: Elderly people, especially those over 70, have a significantly longer GRT.  
 Posture: GRT can vary between supine and upright ambulatory states of the 
patient.  
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 Concomitant drug administration: Anticholinergics like atropine, 
propantheline, opiates like codeine and prokinetic agents like Metoclopramide 
and Cisapride, can affect floating time.        
 Biological factors: Diabetes and Crohn’s disease etc. 
 
Approaches to Gastric retention  
Various approaches for gastro retentive drug delivery systems are:  
 
(A) Floating drug delivery 
(B) Bio/Muco-adhesive systems 
(C) Raft-forming systems 
(D) Swelling and expanding systems 
(E) Superporous Hydrogels 
(F) High density systems 
 
(A)Floating drug delivery 
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric 
fluids and thus remain buoyant in the stomach (Bardonnet P.L et al., 2006), (Fig.3), for 
a prolonged period of time, without affecting the gastric emptying rate and the drug is 
released slowly at a desired rate from the system, results in an increase in the gastric 
residence time and a better control of fluctuations in the plasma drug concentrations and 
after complete release of the drug, the residual system is emptied from the stomach. 
Chapter-II                                                                     GRDDS 
 
Madurai Medical College Page 23 
 
 
Fig: 3 Graphic of the buoyant tablet which is less dense than the stomach fluid and 
therefore remains in the fundus. 
(B) Bio/Muco-adhesive systems 
  Bio/muco-adhesive systems, bind to the gastric epithelial cell surface or mucin, 
which extends the GRT of drug delivery system in the stomachThe surface epithelial 
adhesive properties of mucin have been well recognized and applied to the development 
of GRDDS based on bio/muco-adhesive polymers (Fig 4). The ability to provide 
adhesion of a drug delivery system to the gastrointestinal wall provides longer 
residence time in a particular organ site, thereby producing an improved effect in terms 
of local action or systemic effect. Binding of polymers to the mucin/epithelial surface 
can be divided into three categories:   
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Fig: 4 Bioadhesive systems 
 
(C)  Raft-forming systems: 
These systems (Bardonnet P.L et al., 2006), contain gel-forming solution (e.g. 
sodium alginate solution containing carbonates or bicarbonates), which on contact with 
the gastric contents, swells and forms a viscous cohesive gel containing entrapped CO2 
bubbles, releases drug slowly in stomach by forming the raft layer on the top of gastric 
fluid (Fig.5). These formulations contain antacids such as calcium carbonate or 
aluminium hydroxide to reduce gastric acidity.  
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Fig: 5 Barrier formed by a raft-forming system 
 
(D) Swelling and expanding systems:  
A dosage form in the stomach will withstand gastric transit if it is bigger than 
the pyloric sphincter, also the dosage form must be small enough to be swallowed, and 
must not cause gastric obstruction either singly or by accumulation (Bardonnet P.L et 
al., 2006). Thus, their configurations are required to develop an expandable system in 
order to prolong the gastric retention time (GRT), 
 
1) A small configuration for oral intake. 
2) An expanded gastroretentive form. 
3) A final small form enabling evacuation following drug release from the 
device. Swellable systems, (Fig.6), are also retained in the gastro intestinal tract (GIT) 
due to their mechanical properties. The swelling is usually results from osmotic 
absorption of water and the dosage form is small enough to be swallowed by the gastric 
fluid.   
• Expandable systems have some drawbacks like problematical storage of much 
easily hydrolysable, biodegradable polymers relatively short-lived mechanical 
shape memory for the unfolding system most difficult to industrialize and not 
cost effective. Again, permanent retention of rigid, large single-unit expandable 
drug delivery dosage forms may cause brief obstruction, intestinal adhesion and 
gastropathy. 
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Fig: 6 Drug release from swellable systems 
 
Thus, gastro retentivity is improved by the combination of substantial dimension with 
high rigidity of dosage form to withstand peristalsis and mechanical contractility of the 
stomach. Unfoldable and swellable systems have been investigated and recently tried to 
develop an effective gastro retentive drug delivery.  
Unfoldable and swellable systems have been investigated and recently tried to 
develop an effective gastro retentive drug delivery. 
Unfoldable systems are made of biodegradable polymers. They are available in 
different geometric forms, like tetrahedron, ring or planner membrane (4 - label disc or 
4 - limbed cross form) of bioerodible polymer compressed within a capsule which 
extends in the stomach.   
 
(E)  Superporous Hydrogels: 
Conventional hydrogels, with pore size ranging between 10 nm and 10 µm has 
very slow process of water absorption and require several hours to reach an equilibrium 
state during which premature evacuation of the dosage form may occur while the 
superporous hydrogel (Bardonnet P.L et al., 2006), (Fig.7), having average pore size 
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(>100 µm), swell to equilibrium size within a minute, due to rapid water uptake by 
capillary wetting through numerous interconnected open pores. Moreover they swell to 
a large size (swelling ratio 100 or more) and are intended to have sufficient mechanical 
strength to withstand pressure by gastric contractions. This is achieved by a co- 
formulation of a hydrophilic particulate material, Ac-Di-Sol (Croscarmellose sodium). 
 
 
 
 
Fig:7 On the left, Superporous Hydrogels in its dry (a) and water-swollen (b) state. 
On the right, schematic illustration of the transit of Superporous Hydrogel. 
 
(F) Magnetic systems: 
This approach is based on the simple principle that the dosage form contains a 
small internal magnet, and a magnet placed on the abdomen over the position of the 
stomach to enhance the gastric retention time (GRT) (Bardonnet P.L et al., 2006),.  The 
external magnet must be positioned with a degree of high precision that might 
compromise patient compliance. 
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 (G) Self-unfolding systems: 
 
The self-unfolding systems are capable of mechanically increasing in size 
relative to the initial dimensions. This increase prevents the system from passing 
through the pylorus and retains for a prolonged period of time in the stomach. A drug 
can be either contained in a polymeric composition of the gastro retentive system or 
included as a separate component. Several methods, were suggested to provide for the 
self-unfolding effect 
• The use of hydrogels swelling in contact with the gastric juice. 
• Osmotic systems, comprising an osmotic medium in a semi-permeable 
membrane 
• Systems based on low-boiling liquids converting into a gas at the body 
temperature 
 
(H) High density systems: 
These systems with a density of about 3 g/cm
3
 are retained in the rugae of the 
stomach and are capable of withstanding its peristaltic movements. A density of 2.6-2.8 
g/cm
3
 acts as a threshold value after which such systems can be retained in the lower 
part of the stomach. High density formulations include coated pellets. Coating is done 
by heavy inert material such as barium sulphate, zinc oxide, titanium dioxide, iron 
powder etc. They are retained in the antrum of stomach, (Fig.8). 
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Fig: 8 Graphic of heavy tablet which is denser than the stomach fluid and 
therefore sinks to the antrum 
 
 
Floating drug delivery systems:
 
 
A floating dosage form is useful for drugs acting locally in the proximal 
gastrointestinal tract. These systems are also useful for drugs that are poorly soluble (or) 
unstable in intestinal fluids. The floating properties of these systems help to retain in the 
stomach for a long time. Various attempts have been made to develop floating systems, 
which float on the gastric contents and release drug molecules for the desired time 
period. After the release of a drug, the remnants of the system are emptied from the 
stomach.  
 
Based on the mechanism of buoyancy, two different technologies have been 
used in development of floating drug delivery systems. These include: 
 
a) Effervescent system. 
b) Non- Effervescent system. 
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a) Effervescent Systems 
 
Effervescent systems,  include use of gas generating agents, carbonates (e.g. 
Sodium bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present in 
the formulation to produce carbon dioxide (CO2) gas, thus reducing the density of the 
system and  making it float on the gastric fluid. An alternative is the 
incorporation  of  matrix containing  portion  of  liquid, which produce gas that 
evaporate at body temperature 
. 
 
 Fig: 9 Gas generating systems 
 
These effervescent systems further classified into two types: 
 
1)      Gas generating systems. 
2)      Volatile liquid or vacuum containing systems. 
 
1) Gas generating systems 
A) Tablets:  
 
1. Intragastric single layer floating tablets or Hydrodynamically Balanced 
System     (HBS)   
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These formulations have bulk density lower than gastric fluids and thus float in 
the stomach that increases the gastric emptying rate for a prolonged period, (Fig.10). 
These are formulated by intimately mixing the gas (CO2) generating agents and the 
drug within the matrix tablet.  The drug is released slowly at a desired rate from the 
floating system and the residual system is emptied from the stomach after the complete 
release of the drug. This leads to an increase in the gastric residence time (GRT) and a 
better control over fluctuations in plasma  drug concentration. 
 
 
Fig 10 Intragastric single layer floating tablet 
 
2. Intragastric bilayer floating tablets  
These are also compressed tablets, containing two layers (Fig.11): 
 Immediate release layer 
  Sustained release layer.   
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Fig 11: Intragastric bilayer floating tablet 
B) Floating capsules 
These floating capsules are formulated by filling with a mixture of sodium 
alginate and sodium bicarbonate. The systems float as a result of the generation of CO2 
that was trapped in the hydrating gel network on exposure to an acidic environment.  
 
C) Multiple unit type floating pills 
  These multiple unit type floating pills are sustained release pills, known as 
‘seeds’, which are surrounded by two layers. The outer layer is of swellable membrane 
layer while the inner layer consists of effervescent agents. This system sinks at once 
and then it forms swollen pills like balloons which float as they have lower density, 
when it is immersed in the dissolution medium at body temperature. The lower density 
is due to generation and entrapment of CO2 within the system. 
 
D) Floating system with Ion-Exchange resins 
Floating system using bicarbonate loaded ion exchange resin was made by 
mixing the beads with 1M sodium bicarbonate solution, and then the semi-permeable 
membrane is used to surround the loaded beads to avoid sudden loss of CO2. On contact 
with gastric contents an exchange of bicarbonate and chloride ions takes place that 
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results in generation of CO2 that carries beads towards the top of gastric contents and 
producing a floating layer of resin beads. 
 
 
 
  
2) Volatile liquid or vacuum containing systems 
            (a)      Intragastric floating gastrointestinal drug delivery system 
This system floats in the stomach because of floatation chamber, which is 
vacuum or filled with a harmless gas or air, while the drug reservoir is encapsulated 
by a microporous compartment. 
 
(b)      Inflatable gastrointestinal delivery systems   
These systems are incorporated with an inflatable chamber, which contains 
liquid ether that gasifies at body temperature to inflate the chamber in the stomach. 
These systems are fabricated by loading the inflatable chamber with a drug reservoir, 
which can be a drug, impregnated polymeric matrix, then encapsulated in a gelatine 
capsule. After oral administration, the capsule dissolves to release the drug reservoir 
together with the inflatable chamber. The inflatable chamber automatically inflates and 
retains the drug reservoir compartment in the stomach. The drug is released 
continuously from the reservoir into gastric fluid. 
 
c)      Intragastric osmotically controlled drug delivery system 
This system is comprised of an osmotic pressure controlled drug delivery device 
and an inflatable floating support in a biodegradable capsule, On contact with the 
gastric contents in the stomach, the capsule disintegrates quickly to release the 
intragastirc osmotically controlled drug delivery device. The inflatable support inside 
forms a hollow polymeric bag which contains a liquid that gasifies at body temperature 
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to inflate the bag and it is deformable. The osmotic pressure controlled drug delivery 
device consists of two components, osmotically active compartment and a drug 
reservoir compartment. The drug reservoir compartment is enclosed by a pressure 
responsive collapsible bag, which is impermeable to liquid and vapour and has a drug 
delivery orifice. The osmotically active compartment contains an osmotically active salt 
and is enclosed within a semi-permeable housing. In the stomach, the osmotically active 
salt present in the osmotically active compartment is dissolved by absorbing the water 
continuously present in the GI fluid through the semi-permeable membrane. An osmotic 
pressure is thus created which acts on the collapsible bag and in turn forces the drug 
reservoir compartment to reduce its volume and activate the drug reservoir 
compartment to reduce its volume and activate the drug release of a drug solution 
formulation through the delivery orifice. The floating support is also made to contain a 
bioerodible plug that erodes after a predetermined time to deflate the support. The 
deflated drug delivery system is then emptied from the stomach. 
 
 
Fig: 12 Intragastric osmotically controlled drug delivery system 
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b) Non-Effervescent systems 
The Non-Effervescent floating drug delivery systems are based on mechanism 
of swelling of polymer or bioadhesion to mucosal layer in GI tract. The various types of 
this system are: 
1)      Single layer floating tablets: 
These are formulated by intimate mixing of drug with a gel forming hydrocolloid, that 
swells on contact with gastric fluid and maintain bulk density of less than unity. The air 
trapped by the swollen polymer confers buoyancy to these dosage forms. 
 2)      Bilayer floating tablets 
        A bilayer tablet contain two layer one immediate release layer which release 
initial dose                   from system while the another sustained release layer absorbs gastric 
fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a bulk 
density of less than unity and thereby it remains buoyant in the stomach.
 
 
3)      Alginate beads 
Multi unit floating dosage forms were developed from freeze dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by 
dropping a sodium alginate solution into aqueous solution of CaCl2, causing 
precipitation of calcium alginate leading to formation of porous system, which can 
maintain a floating force for over 12 hours. When compared with solid beads, which 
gave  a short  residence, time of 1 hr, and these floating beads gave a prolonged 
residence time of more than 5.5 hours.  
  
4) Hollow microspheres 
Hollow microspheres (microballons), loaded with drug in their outer polymer 
shells were prepared by a novel emulsion-solvent diffusion method (Xiaoling Li, 
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Bhaskara R. Jasti, 2005) (Fig.13). The ethanol: dichloromethane solution of the drug 
and an enteric acrylic polymer was poured into an agitated aqueous solution of PVA 
that was thermally controlled at 40
0
C. The gas phase generated in dispersed polymer 
droplet by evaporation of dichloromethane formed an internal cavity in microsphere of 
polymer with drug. The microballons floated continuously over the surface of acidic 
dissolution media containing surfactant for more than 12 hours in vitro (Alexander 
Streubel et al., 2006).  
 
 
Fig: 13 Formulation of floating hollow microsphere or microballoon 
 
 EVALUATION OF FLOATING DOSAGE FORMS 
1. For Single Unit Dosage Forms (ex: tablets). (Baumgartner S et al.,2000 & Rosa 
M. et al.,1994) 
(i) Floating lag time: It is the time taken by the tablet to emerge onto the surface of 
dissolution medium and is expressed in seconds or minutes. 
(ii) Invitro drug release and duration of floating: This is determined by using USP II 
apparatus (paddle) stirring at a speed of 50 or 100 rpm at 37 ± 0.2 °c in simulated 
gastric fluid (pH 1.2 without pepsin). Aliquots of the samples are collected and 
Chapter-II                                                                     GRDDS 
 
Madurai Medical College Page 37 
 
analysed for the drug content. The time (hrs) for which the tablets remain buoyant on 
the surface of the dissolution medium is the duration of floating and is visually 
observed. 
(iii) In vivo evaluation for gastro-retention: This is carried out by means of X-ray or 
Gammascintigraphic monitoring of the dosage form transition in the GIT. The tablets 
are also evaluated for hardness, weight variation, etc. 
2. For Multiple Unit Dosage Forms (ex: microspheres) Apart from the In vitro 
release, duration of floating and in vivo gastro-retention tests, the multiple unit dosage 
forms are also evaluated for 
(i) Morphological and dimensional analysis with the aid of scanning electron 
microscopy (SEM). The size can also be measured using an optical microscope. 
(ii) % yield of microspheres: This is calculated from Weight of microspheres obtained 
×100 / total weight of drug 
and polymer 
(iii) Entrapment efficiency: The drug is extracted by a suitable method, analysed and is 
calculated from 
Practical amount of drug present ×100 / Theoretical drug content 
(iv) In vitro floating ability (Buoyancy %): A known quantity of microspheres are 
spread over the surface of a USP (Type II) dissolution apparatus filled with 900 ml of 
0.1 N HCl containing 0.002% v/v Tween 80 and agitated at 100 rpm for 12 hours. After 
12 hours, the floating and settled layers are seperated, dried in a dessicator and 
weighed. 
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The buoyancy is calculated from the following formula. 
Buoyancy (%) = Wf / ( Wf + Ws) * 100 
Where, Wf and Ws are the weights of floating and settled microspheres respectively. 
(v) Drug-excipient (DE) interactions: This is done using FTIR. Appearance of a new 
peak, and/or disappearance of original drug or excipient peak indicate the DE 
interaction. Apart from the above mentioned evaluation parameters, granules (ex: 
Gelucire 43/01) are also evaluated for the effect of ageing with the help of Differential 
Scanning Calorimeter or Hot stage polarizing microscopy. 
CHARACTERIZATION PARAMETERS: 
1. Size and shape evaluation: 
The particle size and shape plays a major role in determining solubility rate of the drugs 
and thus potentially its bioavailability. The particle size of the formulation was 
determined using Sieve analysis, Air elutriation analysis, Photo analysis, Optical 
microscope ,Electro résistance counting methods (Coulter counter), Sedimentation 
techniques, Laser diffraction methods, ultrasound attenuation spectroscopy, Air 
Pollution Emissions Measurements etc. 
2.  Floating Properties: 
Effect of formulation variables on the floating properties of gastric floating drug 
delivery system was determined by using continuous floating monitoring system and 
statistical experimental design. 
3.  Surface Topography: 
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The surface topography and structures were determined using scanning electron 
microscope (SEM, JEOL JSM – 6701 F, Japan) operated with an acceleration voltage 
of 10k.v, Contact angle meter, Atomic force microscopy (AFM), Contact profiliometer. 
4.  Swelling Studies: 
Swelling studies were performed to calculate molecular parameters of swollen 
polymers. Swelling studies was determined by using Dissolution apparatus, optical 
microscopy and other sophisticated techniques which include H1NMRimaging, 
Confocal laser scanning  microscopy (CLSM), Cryogenic scanning electron microscopy 
(Cryo-SEM), Light scattering imaging (LSI) etc. The swelling studies by using 
Dissolution apparatus (USP dissolution apparatus (usp-24) labindia disso 2000) was 
calculated as per the following formula. (Ferdous Khan et al., 2008) 
           Swelling ratio = Weight of wet formulation / Weight offormulations 
5.  Determination of the Drug Content: 
Percentage drug content provides how much amount of the drug that was present in the 
formulation. It should not exceed. the limits acquired by the standard monographs. 
Drug content was determined by using HPLC, HPTLC methods, near infrared 
spectroscopy (NIRS), Microtitrimetric methods, Inductively Coupled Plasma Atomic 
Emission Spectrometer (ICPAES) and also by using spectroscopy techniques. 
6. Percentage Entrapment Efficiency: 
Percentage entrapment efficiency was reliable for quantifying the phase distribution of 
drug in the prepared formulations. Entrapment efficiency was determined by using three 
methods such as Micro dialysis method, Ultra centrifugation, and pressure Ultra 
filtration. 
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7.  In-vitro Release Studies: 
In vitro release studies (USP dissolution apparatus (USP- 24) lab India disso 2000) 
were performed to provide the amount of the drug that is released at a definite time 
period. Release studies were performed by using Franz diffusion cell system and 
synthetic membrane as well as different types of dissolution apparatus. 
8. Powder X-ray Diffraction: 
X-ray powder diffraction (Philips analytical, modelpw1710) is the predominant tool for 
the study of poly-crystalline materials and is eminently suited for the routine 
characterization of pharmaceutical solids. Samples were irradiated with α radiation and 
analyzed between 2 ºC and 60 ºC .The voltage and current used were 30KV and 30mA 
respectively. 
9. Fourier Transform Infrared Analysis: 
Fourier transform infrared spectroscopy (FT-IR, Shimadzu, Model-RT-IR-8300) is a 
technique mostly used to identify organic, polymeric, and some inorganic materials as 
well as for functional group determination. Fourier Transform Infrared Analysis (FT-
IR) measurements of pure drug, polymer and drug loaded polymer formulations were 
obtained on FTIR. The pellets were prepared on KBr-press under hydraulic pressure of 
150kg/cm2; the spectra were scanned over the wave number range of 3600 to 400 cm-1 
at the ambient temperature. 
10. Differential Scanning Calorimetric (DSC): 
DSC (Shimadzu, Model-DSC-60/DSC-50/ Metler Toldeo) are used to characterize 
water of hydration of pharmaceuticals .Thermo grams of formulated preparations were 
obtained using DSC instrument equipped with an intercooler. Indium/Zinc standards 
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were used to calibrate the DSC temperature and enthalpy scale. The sample 
preparations were hermitically sealed in an aluminium pan and heated at a constant rate 
of 10°C/min; over a temperature range of 25° C – 65°C. Inert atmosphere was 
maintained by purging nitrogen gas at the flow rate of 50ml/min. 
 
III) IN-VIVO EVALUATION 
a) Radiology 
X-ray is widely used for examination of internal body systems. Barium Sulphate is 
widely 
used Radio Opaque Marker. So, BaSO4 is incorporated inside dosage form and X-ray 
images are taken at various intervals to view the dosage form. 
b) Scintigraphy 
Similar to X-ray, emitting materials are incorporated into dosage form and then images 
are 
taken by scintigraphy. Widely used emitting material is 99Tc. 
c) Gastroscopy 
Gastroscopy is peroral endoscopy used with fibre optics or video systems. Gastroscopy 
is used to inspect visually the effect of prolongation in stomach. It can also give the 
detailed evaluation of GRDDS. 
d) Magnetic Marker Monitoring 
In this technique, dosage form is magnetically marked with incorporating iron powder 
inside, and images can be taken by very sensitive bio-magnetic measurement 
equipment. Advantage of this method is that it is radiation less and so not hazardous. 
e) Ultrasonography 
Used sometimes, not used generally because it is not traceable at intestine. 
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 Advantages of floating drug delivery system 
• The principle of Hydrodynamically Balanced System (HBS) can be used for any 
particular medicament or class of medicament. The HBS formulations are not 
restricted to medicaments, which are principally absorbed from the stomach, 
since it has been found that these are equally efficacious with medicaments 
which are absorbed from the intestine. E.g. Chlorpheniramine maleate. 
• The HBS are advantageous for drugs absorbed through the stomach e.g. ferrous 
salts and for drugs meant for local action in the stomach and treatment of peptic 
ulcer disease e.g. antacids. 
• The efficacy of the medicaments administered utilizing the sustained release 
principle of HBS has been found to be independent of the site of absorption of 
the particular medicaments. 
• Administration of a prolonged release floating dosage form tablet or capsule 
will result in dissolution of the drug in gastric fluid. After emptying of the 
stomach contents, the dissolved drug is available for absorption in the small 
intestine, therefore it is expected that a drug will be fully absorbed from the 
floating dosage form if it remains in solution form even at alkaline p
H
 of the 
intestine.  
• Many drugs categorized as once-a-day delivery have been demonstrated to 
have suboptimal absorption due to dependence on the transit time of the dosage 
form, making traditional extended release development challenging. Therefore, 
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a system designed for longer gastric retention will extend the time within which 
drug absorption can occur in the small intestine.  
• When there is vigorous intestinal movement and a short transit time as might 
occur in certain type of diarrhoea, poor absorption is expected under such 
circumstances it may be advantageous to keep the drug in floating condition in 
stomach to get a relatively better response.  
• Gastric retention will provide advantages such as the delivery of drugs with 
narrow absorption windows in the small intestinal region. 
 Limitations of floating drug delivery system 
• The floating system requires, sufficiently high level of fluid in the stomach for 
the system to float, this can be overcome by administering dosage form with a 
glass full of water (200-250 ml) or coating the dosage form with bioadhesive 
polymer which adhere to gastric mucosa.  
• Aspirin and non-steroidal anti-inflammatory drugs are known to cause gastric 
lesions, and slow release of such drugs in the stomach is unwanted.  
• Drugs, such as Isosorbide dinitrate, that are absorbed equally throughout the GI 
tract, drugs undergoing first pass metabolism will not benefit from incorporation 
into a gastric retention system.  
• Floating dosage form should not be given to the patients just before going to the 
bed as gastric emptying occurs rapidly when the subject remains in supine 
posture.  
• Drugs that have stability or solubility problem in gastrointestinal fluid or that 
irritate gastric mucosa are not suitable.  
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• Drugs that have multiple absorption sites or which undergo first pass 
metabolism were not desirable.  
• The single unit floating dosage form is associated with “all or none concept”. 
This problem can be overcome by formulating multiple unit system like floating 
microballoons or microspheres.  
 
Applications of floating drug delivery system 
    Sustained drug delivery: 
   Hydrodynamically Balanced System (HBS) type are dosage forms which have 
bulk density less than one, relatively large in size and did not easily pass through 
pylorus,                     releases the drug over a prolonged period of time by retaining in 
the stomach for several hours  and by increasing the gastric residence time (Manoj 
Goyal et al., 2011).  
 Site specific drug delivery: 
Floating drug delivery systems are particularly useful for drugs having specific 
absorption from stomach or proximal part of the small intestine e.g. riboflavin, 
furosemide etc. The absorption of captopril has been found to be site specific, 
stomach being the major site followed by duodenum (Manoj Goyal et al., 2011)..  
          Absorption enhancement: 
Drugs that have  poor bioavailability, because of their 
absorption  is  restricted  to upper  GIT are potential candidates  to be formulated 
as  floating drug delivery systems, thereby improving  their  absolute  bioavailability 
(Manoj Goyal et al., 2011)..  
 
              Minimized adverse activity at the colon  
Chapter-II                                                                     GRDDS 
 
Madurai Medical College Page 45 
 
Retention of the drug at the stomach (HBS system), minimizes the amount of 
drug that reaches the colon, that prevents the undesirable activities of the drug in 
colon (Manoj Goyal et al., 2011). This Pharmacodynamic aspect provides the rationale 
for GRDF formulation for betalactam antibiotics that are absorbed only from the small 
intestine, and whose presence in the colon leads to the development of microorganism’s 
resistance. 
Reduction in plasma fluctuations: 
Patients with advanced Parkinson’s disease, experienced pronounced 
fluctuations in symptoms while treatment with standard L-dopa.  A HBS dosage 
form provided a better control of motor fluctuations although its bioavailability was 
reduced by 50-60% of the standard formulation (Manoj Goyal et al., 2011). 
Peptic ulcer treatment: 
H. Pylori, causative bacterium for peptic ulcers and chronic gastritis. Patients 
require high concentration of drug, to be maintained at the site of infection that is within 
the gastric mucosa. The floating dosage form due to its floating ability was retained in 
stomach and maintained high concentration of drug in the stomach. A sustained liquid 
preparation of Ampicillin, using sodium alginate was developed that spreads out and 
adheres to gastric mucosal surfaces and releases the drug continuously. 
Suitable for poorly absorbed drugs. 
 Floating drug delivery systems are particularly useful for drugs which are 
poorly soluble or unstable in intestinal fluids and acid stable drugs and for those which 
undergo abrupt changes in their pH-dependent solubility due to pathophysiological 
conditions of GIT, food and age, e.g. floating system for furosemide lead to 
potential treatment of Parkinson’s disease. Approximate 30% drug was absorbed after 
oral administration.  
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CHAPTER-III 
LITERATURE REVIEW 
Anand Gadad et al., 2011, developed and evaluated floating microspheres of 
captopril to prolong its gastric residence time in stomach. Floating microspheres 
was formulated using bio compatible polymers like Eudragit S100 and Ethyl 
cellulose in different proportion by solvent evaporation technique. The microsphere 
with Ethlcellulose showed higher buoyancy when compared with Eudragit S100 
polymer.  
 
Gangadharappa H. V et al., 2011,  developed and evaluated Hollow Microspheres 
of Rosiglitazone Maleate, Microspheres were prepared by modified Quasi-emulsion 
diffusion technique using ethyl cellulose, eudragit S100, polyethylene oxide and 
Hydroxyproply methyl cellulose (HPMC K15M) as polymers. The formulations 
were evaluated for micromeritic properties, in vitro, in vivo buoyancy, % yield, 
entrapment efficiency, in vitro and in vivo release studies. SEM photographs 
showed the outer surface of microspheres was smooth and dense whereas internal 
surface was porous which helped to prolong floating to increase residence time in 
stomach. All the formulations floated for more than 8 h. In vitro drug release studies 
showed controlled release of rosiglitazone maleate for over 12 h. The release 
behaviour best fitted mostly in peppas and zero order equations. In vivo evaluation 
of blood glucose levels in albino rats showed that floating microspheres of 
rosiglitazone maleate had better glycemic control than conventional dosage form. 
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Mallikarjuna Rao K et al., 2011, prepared and evaluated floating microspheres 
with Amoxycillin trihydrate as a model drug for prolongation of gastric residence 
time. The microspheres were prepared by the Non-aqueous solvent diffusion 
method using polymers HPMC and Ethyl cellulose. By the observation of all 
formulation results concluded that D: Polymer (1:2), polymer Ec:HPMC 
(1.5gm:0.5gm) containing formulation showed the better drug release. 
 
Kumar Darapu B N et al., 2011, formulated and evaluated Gastroretensive 
Floating Microspheres of Ranitidine Hydrochloride by using HPMC K 100, 
Xanthan gum and Eudragit S‐100 and in various ratios of 1: 1, 1: 2, and 1: 3. The 
formulations were evaluated for FTIR, drug loading, % entrapment, particle size, 
SEM, buoyancy, dissolution study and the drug release kinetics. Comparison of 
three polymers revealed HPMC to be a suitable candidate for sustained release. 
 
M.Saravanan, B.Anupama., 2011,  developed and evaluated Ethyl cellulose and 
PEG blend floating microspheres loaded with ranitidine hydrochloride by novel 
solvent evaporation matrix erosion method. PEG employed as pore forming agent to 
induce buoyancy. The drug loaded microsphere could float for 10 hrs and sustain 
the drug release over 4 to 6 hrs. 
 
Yuanfen Liu et al., 2011, produced hollow and bio adhesive microspheres to 
lengthen drug retention time in the stomach. In these microspheres, ethyl cellulose 
was used as the matrix, Eudragit EPO was employed to modulate the release rate, 
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and glyceryl monooleate (GMO) was the bio adhesive polymer insitu. 
Pharmacokinetic analysis indicated that the elimination half-life time of the hollow 
bio adhesive microspheres was prolonged and that the elimination rate was 
decreased.  
 
Amol V. Pande et al., 2010, done a project on in-vitro and in-vivo evaluation of 
ethyl cellulose based floating microspheres of cepodoxime proxetil. GRDDS for 
cepodoxime proxetile using EC & HPMC as a release retarded material by solvent 
evaporation technique. In-vivo studies revealed that the relative bioavailability of 
the drug increased by more than 1.5 times by formulating in to microspheres. From 
the result it can be concluded that biocompatible and cost effective polymer like EC 
can be used to formulate an efficient floating micro particulate system with good 
percentage Entrapment efficiency and practical yield. 
 
Anitha Kakkaerle et al., 2010, developed to prolong gastric residence time by 
floating matrix tablets of Alfuzosin hydrochloride. The tablets were prepared by 
direct compression and melt granulation technique, using polymers such as HPMC 
K15, SCMC, Compritol 888 ATO and either alone or in combination, and other 
excipients. Prepared tablets were evaluated in-vitro as well as in vivo studies. In-
vivo studies showed that the tablets retained in stomach for 6 hours. It was 
concluded that. HPMC K15 alone retarded the drug release for highly water soluble 
drug for period of 12 hours. 
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C.Sharon Kumar et al., 2010, done a project on formulation and evaluation of 
floating microspheres of Gabapentin by using solvent evaporation method using 
different ratio of sodium alginate polymer. The increase of polymer concentration 
the drug release was retard. The release kinetics of gabapentin followed super case 
II transport diffusion. 
 
Ghodake J.D et al., 2010, done a project on formulation and evaluation of floating 
microspheres containing Anti-diabetic (Metformin hydrochloride) drug, the floating 
microspheres prepared by the emulsion solvent diffusion technique using polymers 
HPMC K4M and Eudragit RS100. The developed floating microsphere of 
Metformin hydrochloride may be used in clinic for prolonged drug release in 
stomach for at least 8hrs, thereby improving the bioavailability and patient 
compliance. 
 
M.Najmuddin et al., 2010, developed floating microspheres of ketoprofen were 
repared by solvent evaporation method using HPMC and two different grades of 
Ethyl cellulose as a polymer. The HPMC & Ethyl cellulose which exhibit excellent 
percentage yield, in-vitro buoyancy, Entrapment efficiency and drug release 98.88% 
for a period of 12 hrs. 
 
Mona Semaity et al., 2010, prepared and characterized gastroretentive floating 
microspheres of ofloxacin hydrochloride. Formulation of ofloxacin Hcl were 
prepared as floating microsphere by solvent diffusion technique using polymers 
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such as EC, PVP K90 and PVA in different ratio. In-vitro floatability studies 
revealed that most of the microspheres (52.5% to 95.5%) were floatable. It was 
concluded that these floating microsphere can be selected for the development of 
gastroretentive drug delivery system of ofloxacin Hcl for potential therapeutic uses. 
Najmuddin. M et al., 2010, developed and evaluated floating microspheres of 
ketoprofen, Ketoprofen is NSAID drug with short elimination half-life. Floating 
microspheres of ketoprofen were prepared by solvent evaporation method using 
HPMC and two different grades of Ethyl cellulose polymers. The floating 
microspheres were evaluated such as micromeritic properties, percentage yielg, 
particle size, drug content determination, Encapsulation efficiency, In-vitro 
buoyancy In-vitro drug release, drug compatibily studies, and SEM studies. The 
results showed that as the concentration of polymer increased it affects the particle 
size, percentage yield, in-vitro buoyancy and drug release of microsphere. The 
results of these studies suggest that floating microspheres of ketoprofen can be 
successfully designed to develop sustained drug delivery which can reduce dosing 
frequency. 
 
Pandey Manisha et al., 2010, formulated and evaluated floating microspheres of 
famotidine. Floating microspheres were prepared by solvent evaporation method 
using HPMC and Ethyl cellulose as a rate controlling polymer. The developed 
formulation showed prolonged drug release in stomach for at least 12hrs. 
Rajeev Garg and GD Gupta., 2010, prepared and evaluated floating microspheres 
of silymarin for prolonged gastric residence time and increased drug bioavailability. 
The work concluded tha the prepared formulation with a suitable blend of Eudragit 
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S with Eudragit RL and HPMC with Ethyl cellulose, demonstrated satisfactory 
release and floating properties. Drug release from the formulation followed zero 
order kinetics and the mechanism of drug release was diffusion controlled. 
 
Sharon Kumar. C et al., 2010, was prepared and characterized floating 
microspheres of gabapentin by using the solvent evaporation method. The prepare 
microspheres were evaluated for different evaluation parameters such as percentage 
yielg, particle size, drug content determination, Encapsulation efficiency, In-vitro 
drug release. Increased in polymer concentration the drug release was controlled. 
The release kinetics of gabapentin followed supercase II transport diffusion. 
 
Chudiwal P.D et al., 2009, developed and optimized gastroretentive drug delivery 
system of clarithromycin floating microspheres by the optimization technique. The 
clarithromycin microspheres prepared by non-aqueous solvent evaporation method 
using different grades of HPMC such as HPMC 15M, HPMC K4M, HPMC 100LV 
and Ethyl cellulose.  The method for preparation of floating microspheres of 
clarithromycin with optimal yield, Entrapment Efficiency and buoyancy as well as 
optimal release properties was determined using experimental design methodology. 
 
Gattani Y. S et al., 2009, Formulated and evaluated Gastro retentive 
Multiparticulate Drug delivery system of Aceclofenac by the emulsification 
solvent-evaporation technique consisting of eudragit RS 100 as a polymer. Effects 
of polymer concentration, stirring rate during preparation and effect of temperature 
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on size and drug release was evaluated. The prepared microspheres exhibited 
prolonged drug release (> 12h) and remained buoyant for > 12 h. The mean particle 
size increased and the drug release rate decreased at higher polymer concentration. 
In-vitro studies demonstrated diffusion controlled drug release from the 
microspheres. 
 
Madan Mohan Kamila et al., 2009, developed Multiunit Floating Drug Delivery 
System of Rosiglitazone Maleate. By encapsulating the drug into Eudragit® RS100 
through nonaqueous emulsification/solvent evaporation method. The in vitro 
performances of microspheres were evaluated by yield (%), particle size analysis, 
drug entrapment efficiency, in vitro floating behavior, surface topography, drug–
polymer compatibility, crystallinity of the drug in the microspheres, and drug 
release studies. The results showed that floating microspheres could be successfully 
prepared with good yields (69–75%), high entrapment (78-97%), narrow size 
distribution, and desired target release. In vivo evaluation in albino rats suggested 
that floating microspheres of rosiglitazone could be a promising approach for better 
glycemic control. 
 
Ramji Anil Kumar Arza et al., 2009, Formulated and Evaluated Swellable and 
Floating Gastroretentive Ciprofloxacin Hydrochloride Tablets using a combination 
of hydrophilic polymer (hydroxypropyl methylcellulose), swelling agents 
(crospovidone, sodium starch glycolate, and croscarmelose sodium) and 
effervescent substance (sodium bicarbonate). Formulations are evaluated for 
percentage swelling, in vitro drug release, floating lag time, total duration of 
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floating, and mean residence time (MRT) in the stomach. The drug release of 
optimized formulation follows the Higuchi kinetic model, and the mechanism is 
found to be non-Fickian/anomalous according to Krosmeyer–Peppas (n value is 
0.68). A combination of HPMC K100M, crospovidone, and sodium carbonate 
shows the good swelling, drug release, and floating characters than the CIFRAN 
OD® (marketed product). 
V.S.Mastiholimath et al., 2008, done a project on invitro and invivo evaluation of 
ranitidine hydrochloride Ethyl cellulose floating microparticles. The formulated 
microspheres was done by solvent evaporation technique with modification by 
using an Ethanol co-solvent system. From the experimental results it can be 
concluded that biocompatible polymers like Ethyl cellulose can be used to 
formulate an efficient flating microparticulate system with good percentage 
Entrapment Efficiency and practical yield. 
 
Yasunori Miyazalei et al., 2008, done a project on Comparison of gastroretentive 
microspheres and sustained release preparations using theophylline Theophylline 
pharmacokinetic studies were conducted in Beagle dogs, comparing bulk powder, 
commercial sustained-release granules (Theodur™), sustained-release 
microspheres, floatable microspheres and mucoadhesive microspheres. Overall, the 
gastroretentive microspheres improved the extent of bioavailability of theophylline, 
which is absorbable from the entire gastrointestinal tract. 
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Yuveraj singh Tanwar et al., 2007, developed and evaluated floating 
microspheres of verapamil hydrochloride for improving the drug bioavailability by 
prolongation of gastric residence time. The microspheres were prepared by solvent 
diffusion evaporation method using Cellulose acetate, Acrycoat S100 and Eudragit 
S100 as a rate retarding polymers. The floating microsphere of verapamil 
hydrochloride prepared with cellulose acetate, may provided a convenient dosage 
convenient dosage form for achieving best performance regarding flow, release and 
floating properties. 
S.Sunggthongjeen et al., 2006, done a project on preparation and in-vitro 
evaluation of a multi unit floating drug delivery system based on gas formation 
technique. The system consist of the drug containing core pellets prepared by 
extrusion-spheronization process, which are coated with double layer of an inner 
effervescent layer (sodium bicarbonate) and an outer gas entrapped polymeric 
membrane of an aqueous colloidal polymer dispersion (Eudragit RL30D, RS30D) 
only the system using Eudragit RL30D as a gas entrapped polymeric membrane 
could float. Both the rapid floating and the sustained release properties were 
achieved in the multiple unit floating drug delivery systems developed in this 
study. 
 
Yasunori Sato et al., 2004, done a project of In-vitro floating and drug releasing 
behaviours of hollow microspheres (micro balloons)  prepared  by the emulsion 
solvent diffusion method utilizing enteric acrylic polymers co-dissolved with drug 
in a mixture of Dichloromethane and Ethanol. In addition by incorporating a 
polymer such as HPMC within the shell of micro balloons the release rate of 
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riboflavin from the micro balloons could be controlled while maintaining high 
buoyancy. 
 
Umamaheshwari et al., 2003, done a project on floating microspheres bearing 
acetohydroxamic acid for the treatment of Helicobacter pylori. Floating 
polycarbonate microsphere, which have the ability to reside in the gastro intestinal 
tract for an extended period, were prepared by emulsion solvent evaporation 
technique. In-vitro studies confirmed the excellent floating properties of 
polycarbonate microspheres. 
Kamel A.H.EL et al., 2001, prepared and evaluated ketoprofen floating oral 
delivery system. The floating microparticle prepared by emulsion solvent diffusion 
technique. Four different ratios of Eudragit S100 with Eudragit RL were used to 
form the floating microparticles. The formulation containing ES: ERL 1:1 
exhibited high percentage of floating particles in all examined media. 
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CHAPTER-IV 
AIM OF THE WORK 
Oral drug administration still remains the favoured route of choice for delivery 
of drugs into systemic circulation. Some drugs have perfect characteristics for good 
absorption throughout the g.i.t while the others present difficulties due to narrow 
absorption window in stomach and proximal gut, stability problems in intestinal fluids, 
poor solubility in intestine or requirement of  local action in the stomach. Rapid and 
unpredictable gastro intestinal transit could result in partial drug absorption from the 
dosage form leading to reduced efficacy of the administered dose.  
                        Perindopril erbumine {2-Methylpropan-2-amine (2S, 3aS, 7aS)-1-[(2S)-
2-[[(1S)-1-(ethoxycarbonyl) butyl] amino] propanoyl]octahydro - 1 H-indole-2-
carboxylate},  a newer ACE inhibitor is used in the treatment of stable coronary artery 
disease and hypertension. Since the perindopril erbumine is preferentially absorbed in 
the proximal small intestine (narrow absorption window), the drug exhibits oral 
bioavailability problems in conventional dosage forms. 
                       An smart and easy way to improve drug absorption and for releasing the 
drug in a controlled manner is to retain a DDS above the absorption window. Because 
most absorption windows are thought to be located in proximal small intestine, the 
noticeable strategy is to retain the formulation in the stomach (i.e., gastro retention). 
Gastro retention can be achieved via intra-gastric floating systems, sedimentation or 
high density systems, swelling or expandable systems, geometry or modified shaped 
systems and super porous hydro gels. 
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                       High density systems have a technical difficulty in formulating a dosage 
form having a density of 2.4-2.8 kg/cm
2
, bio-adhesive systems may be dislodged from 
its site of adhesion; expandable systems may expand in oesophagus or intestines or 
failed to reduce in size after drug absorption to permit its transit through intestine for 
excretion. 
        The attractive principle of floating drug delivery system is exploited by 
the use of polymers such as semi-synthetic derivatives of cellulose along with 
polysaccharides which float in gastric fluids with a bulk density less than 1. It remains 
buoyant and floats on g.i fluids prolonging GRT.  
                  Multiple-unit floating polymeric drug delivery systems such as floating 
microspheres offer advantages of retaining the dosage form in the upper part of GIT 
for prolonged period and thereby releasing the drug in a controlled manner. Such 
floating devices show more reproducible release profiles over all-or-nothing emptying 
nature or dose-dumping phenomenon associated with single-unit system.  
 
  The present investigation aims to develop floating microspheres of 
perindopril erbumine by double emulsification solvent diffusion method using 
polymer blends of Ethyl cellulose with HPMC, Ethyl cellulose with PVP K30, Ethyl 
cellulose with Eudragit S100, Ethyl cellulose with PVP K90 and Ethyl cellulose alone. 
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CHAPTER-V 
PLAN OF WORK 
Step-I 
PREFORMULATION STUDIES: 
a) Determination of λmax of perindopril erbumine in 0.1M Hydrochloric acid. 
b) Calibration curve for the perindopril erbumine at λmax in 0.1 M Hydrochloric 
acid. 
c) Compatibility Studies: 
i. Differential scanning calorimetric (DSC) studies 
ii. Fourier transforms infra-red spectroscopic (FT-IR) studies        
 
Step-II 
PREPARATION OF FLOATING MICROSPHERES: 
                  Preparation of floating microspheres of perindopril erbumine by using 
different concentrations of mixed polymers (EC, EC+HPMC, EC+PVP K30, 
EC+ES100, EC+PVP K 90) by using double emulsion solvent diffusion technique. 
Step-III        
CHARACTERIZATION OF FLOATING MICROSPHERES: 
a) Determination of percentage yield 
b) Determination of particle size 
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c) Determination of Entrapment Efficiency 
d) Determination of in-vitro Percentage Buoyancy 
e) In-vitro release studies 
f) Kinetic analysis of release data. 
 
Step –IV 
SELECTION OF BEST FORMULATION 
The best formulation is selected depending on the results obtained from 
 Percentage yield 
 Entrapment efficiency 
 Percentage buoyancy 
 In-vitro release patterns 
 Release kinetics 
Step-V 
EVALUATION OF BEST FORMULATION 
1. X-ray diffraction studies 
2. Scanning Electron Microscopic (SEM) analysis 
3. In-vivo studies X-Ray studies. 
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CHAPTER-VI 
MATERIALS AND EQUIPMENTS 
Name of the material Manufacturer 
 
Perindopril Erbumine 
 
Gift sample from Orchid Pharma chennai, India. 
 
HPMC K4M 
 
Gift samples from Orchid Pharma, chennai, India. 
 
Ethyl Cellulose 
 
Gift sample from Orchid Pharma, chennai, India. 
 
Polyvinylpyrrolidine K30 
 
Nice Chemicals,kochi, India. 
 
Polyvinylpyrrolidine K90 
 
Nice Chemicals,kochi, India. 
 
Eudragit S100 
 
Gift sample from Orchid Pharma, chennai, India. 
 
Liquid paraffin 
 
Universal Scientific Appliances, India. 
 
Acetone 
 
Central Drug House (P) Ltd, New Delhi, India. 
 
Isopropyle alcohol 
 
Central Drug House (P) Ltd, New Delhi, India. 
 
Dichloromethane 
 
Central Drug House (P) Ltd, New Delhi, India. 
 
Ethanol 
 
Central Drug House (P) Ltd, New Delhi, India. 
 
Span 80 
 
Universal Scientific Appliances 
 
Hydrochloric acid 
 
Nice Chemicals,kochi, India.  
 
Cyclohexane 
 
Central Drug House (P) Ltd, New Delhi, India. 
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EQUIPMENTS: 
 
 
 
Electronic Weighing Balance 
 
 
A & D Company HR 200, Japan 
 
Mechanical Stirrer (Lab Stirrer) 
 
Remi Motors,India 
 
UV Visible Spectrophotometer 
 
Shimadzhu, Japan 
  
Digital Tablet Dissolution Test 
Apparatus
 
Disso 2000, Lab India 
  
Incubator 
 
 
Tempo Industrial Corporation, Bombay, 
India 
Hot air oven 
 
Rands Instruments, chennai, India 
  
X-ray machine  
 
 
Stallion 20, Elpro International Ltd. 
 
Differential Scanning Calorimeter 
 
DSC 60 Shimadzu, Japan 
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CHAPTER-VII 
DRUG PROFILE 
PERINDOPRIL ERBUMINE 
Structure: 
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Chemical name: 
                  (2S, 3αŚ 7αŚ)-1-[(S)-N-[(S)-1-Carboxyl- butyl]   alanyl]      hexahydro-2- indoline 
carboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1). 
Empirical formula: 
                C₁₉H₃₂N₂O₅C₄H₁₁N. 
Description: 
              Nature                                  : white crystalline powder. 
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              Solubility                             : freely soluble in water, alcohol and chloroform 
              Log p                                    :  2.6 
            (Octanol/water) 
              Melting point                       : 126-128˚C       
              Molecular weight                : 441.61 
 Identification:     
             λmax at  208 nm in UV spectrophotometer. 
Pharmacodynamic Properties:   
                        Perindopril an angiotensin –converting enzyme inhibitor, perindopril is a 
prodrug which is converted to active metabolite perindoprilat in liver. Perindoprilat the 
active metabolite competes with angiotensin converting enzyme blocking the conversion of 
angiotensin l to angiotensin II. It is a vasoconstrictor and a negative feedback mediator for 
renin activity. The Lower concentrations results in decrease in blood pressure and an 
increase in plasma renin. Perindoprilat may also act on kininase II; an enzyme identical to 
ACE that degrades vasodilator bradykinin. 
Pharmacokinetic properties: 
Absorption:  
                  Rapid absorption after oral administration. 
                  T max is 1 hour for parent compound, 3to7 hour for active metabolite. 
                   Oral bioavailability         : 75% (perindopril) 
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                                                               25% (perindoprilat) 
Metabolism  
               30 -60 % perindopril is converted to active metabolite perindoprilat in liver by the 
enzyme. 
Excretion: 
     Total body clearance: 219-362ml/min 
     Mean renal clearance: 23.3-28.6ml/min 
Therapeutic indications 
 Hypertension 
 Stable coronary artery disease 
Dose 
      4 mg and 8mg.maximum dose is 16 mg/day 
Adverse effects 
 Postural hypotension 
 Hyperkalemia 
 Cough  
 Angio edema 
 Neutropenia 
 Agranulocytosis 
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 Anaphylactoid reactions 
 Nausea 
 Vomiting  
 Dizziness 
Drug interactions 
Diuretics: 
       Patients on diuretics and especially those started recently, may occasionally experience 
an excessive reduction of blood pressure after initiation of perindopril erbumine therapy. 
The rate and extent of perindopril absorption and elimination are not affected by 
concomitant diuretics. The bio availability of perindoprilat was reduced by diuretics, 
however, and this was associated with a decrease in plasma ACE inhibition. 
Potassium supplements and potassium-sparing diuretics: 
            Perindopril erbumine may be increase serum potassium because of its potential to 
decrease aldosterone production. Use of potassium sparing diuretics (spironolactone, 
amiloride, triamterene and others), potassium supplements or other drugs capable of 
increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase 
the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they 
should be given with caution and the patient’s serum potassium should be monitored 
frequently. 
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Lithium: 
         Increased serum lithium and symptoms of lithium toxicity have been reported in 
patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be 
co administered with caution and frequent monitoring of serum lithium concentration is 
recommended. Use of a diuretic may further increase the risk of lithium toxicity. 
Digoxin 
                 A controlled pharmacokinetic study has shown no effect on plasma digoxin 
concentrations when co administered with perindopril erbumine, but an effect of digoxin 
on the plasma concentration of perindopril/perindoprilat has not been excluded. 
Over dose & Treatment: 
           Symptoms associated with over dosage of ACE inhibitors may include hypotension, 
circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, 
palpitations, bradycardia, dizziness, anxiety, and cough. The recommended treatment of 
over dosage is intravenous infusion of normal saline solution. If hypotension occurs, the 
patient should be placed in the shock position, if available, treatment with angiotensin II 
infusion and /or intravenous catecholamine may also be considered. Perindopril may be 
removed from the general circulation by hemodialysis. Pacemaker therapy is indicated for 
therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations 
should be monitored continuously. 
Prescription: 
                    Yes  
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Generic available: 
                     Immediate- release tablets 
Preparations; 
                     Immediate release tablets -4mg and 8mg. Maximum dose is 16mg/day. 
Storage: 
                  It should be stored in a cool, dark and dry place 
Special precautions: 
 Don't take potassium supplements without seeking medical advice. 
 Don't take during pregnancy. 
Contra-indications: 
 Hypersensitivity to perindopril 
 History of angio edema 
 During pregnancy 
 Hypotension 
Brand names: 
1. Aceon 
2. Coversyl plus 
3. Povinace 
4. Apoperindopril 
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CHAPTER-VIII 
POLYMERS AND EXCIPIENTS PROFILE 
 
ETHYL CELLULOSE 
 
 
Synonyms: 
 Aquacoat ECD 
 Aqualon 
 Ethocel 
 Surelease 
 
Structure: 
 
 
Empirical formula:   
 C12H23O6(C12H22O5)nC12H23O5 
 
Molecular weight:   
 40 0000 
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Description: 
 Color: White to light tancoloured powder. 
 Odour: Odourless. 
 Taste: Tasteless. 
Melting point: 
 165
0 
 - 185
0 
C 
Solubility: 
 Practically insoluble in propylene glycol, glycerine and water  
 Freely soluble in chloroform, ethanol, ethyl acetate, methanol and toluene. 
Functional Category: 
 Coating agent. 
 Flavouring fixative. 
 Tablet binder. 
 Tablet filler. 
 Viscosity-increasing agent.  
Storage Conditions: 
 It should be stored at a temperature not exceeding 328
0 
C (90
0
F) in a dry area 
away from all sources of heat. 
Handling Precautions: 
 To prevent fine dust clouds of ethyl cellulose from reaching potentially 
explosive levels in the air. 
 Its combustible 
 It may be an irritant to the eyes and eye protection should be worn. 
Regulatory status: 
 Included in the FDA inactive ingredients (Raymond C et al., 2006).  
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HYDR
Synonym:  
 Hypromellose. 
 Methocel 
 
Structure: 
Empirical formula:  
 It is partly O-meth
2005).  It is availa
of substitution.  
Molecular weight: 
 10 000 – 1 5 00 00
Description:   
 Colour: White or
 Odour: Odorless 
 Taste: Tasteless
Solubility: 
 Soluble in 
  Practically
  Soluble in
                       POLYMERS AND EXCIPIE
 
OXY PROPYL METHYL CELLULOSE
ylated and O-(2-hydroxy propylated) cellulo
ble in several grades depending upon the vis
0 
 creamy-white fibrous or granular powder. 
 
 
cold water, forming a viscous colloidal soluti
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 Soluble in mixtures of water and alcohol. 
 
Functional Category:   
 Coating agent. 
 Film- former. 
 Stabilizing agent.  
 Tablet binder. 
 Viscosity increasing agent. 
 
Typical Viscosity values for 2 % (w/v) aqueous solutions of different viscosity 
grades of HPMC at 20°C 
 
Methocel K100 Premium LVEP :          100 
Methocel K4M Premium             : 4000 
Methocel K15M Premium   : 15000 
Methocel K100M Premium   : 100 000 
Methocel E4M Premium   : 4000 
Methocel F50 Premium   : 50 
Methocel E10M Premium CR  : 10 000 
Methocel E3 Premium LV  : 3 
Methocel E5 Premium LV   : 5 
Methocel E6 Premium LV   : 6 
Methocel E15 Premium LV   : 15 
Methocel E50 Premium LV   : 50 
Metolose 60SH    : 50, 4000, 10 000 
Metolose 65SH    : 50, 400, 1500, 4000 
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Metolose 90SH    : 100, 400, 4000, 15 000  
 
 
Storage Conditions: 
 
 It should be stored in a well-closed container, in a cool, dry place. 
 
Handling Precautions: 
 Hypromellose dust may be irritant to the eyes and eye protection is 
recommended 
 Excessive dust generation should be avoided to minimize the risks of 
explosion.  
 Hypromellose is combustible (Raymond C et al., 2006). 
 
POLYMETHACRYLAT (EUDRAGIT S100) 
 
Synonyms               
 Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit;                                               
 KollicoatMAE 30 D; Kollicoat MAE 30 DP;  
 polymeric methacrylates. 
 
Nonproprietary names 
                                       BP: Methacrylic acid–ethyl acrylate copolymer  
                                                             (1: 1)       
PhEur:                                                                                           
Acidum methacrylicum et ethylis acrylas 
polymerisatum 
(1: 1) 
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Acidum methacrylicum et ethylis acrylas         
polymerisatum 
(1 : 1) dispersio 30 per centum 
Acidum methacrylicum et methylis methacrylas 
Polymerisatum (1 : 1) 
Acidum methacrylicum et methylis methacrylas 
Polymerisatum (1 : 2) 
Copolymerum methacrylatis butylati basicum 
Polyacrylatis dispersion 30 per centum 
USPNF:             
Ammonio methacrylate copolymer 
Methacrylic acid copolymer 
Methacrylic acid copolymer dispersion 
 
Chemical name  : Poly(methacrylic acid, methyl methacrylate) 1 : 2 
 
Empirical formula  : (C5 H8 O2) n 
Structural formula   
 
          R
1
, R
3
, R
4  
= CH3 
                  R
2 
= H 
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Description     
 Nature   :   White free flowing powder 
 Solubility   : Soluble in acetone and alcohol 
 Molecular weight  : ≥100 000 
 
 Functional categories    
 Film former 
 Tablet binder 
 Tablet diluents 
Properties  
 Loss on drying           :  ≤ 5.0% 
 Methyl methacrylate and 
      methacrylic acid                    : ≤ 0.1% 
 Sulfated ash                           : ≤ 0.1% 
 Apparent viscosity               : 50–200 mPa s 
 Stablility and storage            : Dry powders are stable 
 for at least 3 years if stored in a tightly 
closed 
 container at less than 30ºC. 
 Assay                                   : Methacrylic acid units 27.6–30.7% 
 
 Safety: 
Polymethacrylate copolymers are widely used as film-coating materials in oral 
pharmaceutical formulations. They are also used in topical formulations and are 
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generally regarded as nontoxic and nonirritant materials. A daily intake of 2 mg/kg 
body-weight of Eudragit (equivalent to approximately 150mg for an average adult) may 
be regarded as essentially safe in humans (Raymond C et al., 2006). 
 
Handling Precautions: 
 Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Additional measures should be taken when 
handling organic solutions of polymethacrylates.  
 Eye protection, gloves, and a dust mask or respirator are recommended. 
Polymethacrylates should be handled in wellventilated environment and 
measures should be taken to prevent dust formation.  
 Acute and chronic adverse effects have been observed in workers 
handling the related substances methyl methacrylate and poly(methyl 
methacrylate) (PMMA).(19,20) In the UK, the occupational exposure 
limit for methyl methacrylate has been set at 208 mg/m3 (50 ppm) long-
term (8-hour TWA), and 416 mg/m3 (100 ppm) short-term. 
 
 
 
 
 
 
 
 
 
Chapter – VIII                                       POLYMERS AND EXCIPIENTS PROFILE 
 
Madurai Medical College Page 76 
 
 
                                           POLYVINYLPYRROLIDONE 
 
    
Synonyms 
 E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; 
 polyvidone; polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone Polymer. 
 
 Chemical Name  
1-Ethenyl-2-pyrrolidinone homopolymer 
  
 Empirical Formula and Molecular Weight 
(C6H9NO)n  2500–3 000 000 
 
           The USP 28 describes polyvinylpyrrolidone as a synthetic polymer consisting 
essentially of linear 1-vinyl-2-pyrrolidinone groups, the differing degree of 
polymerization of which results in polymers of various molecular weights (Raymond C 
et al., 2006). It is characterized by its viscosity in aqueous solution, relative to that of 
water, expressed as a K-value, in the range 10–120. The K-value is calculated using 
Fikentscher’s equation.  
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Approximate molecular weights for different polyvinylpyrrolidone grades are 
shown in given Table (Raymond C et al., 2006)   
                                
           K value      Molecular weight 
12 
15 
17 
25 
30 
60 
90 
120 
  2500 
 8000 
10000 
30000 
50 000 
400000 
10 00000 
30 00000 
 
Structural Formula: 
 
 
 
 
 
 Functional Category: 
 
                  Disintegrant; dissolution aid; suspending agent; tablet binder. 
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Applications in Pharmaceutical Formulation: 
 
 Although Polyvinylpyrrolidone is used in a variety of pharmaceutical 
formulations (Raymond C et al., 2006), it is primarily used in solid-dosage 
forms. In tableting, polyvinylpyrrolidone solutions are used as binders in wet 
granulationprocesses. 
 
 Polyvinylpyrrolidone is also added to powder blends in the dry form and 
granulated in situ by the addition of water, alcohol, or hydroalcoholic solutions. 
Polyvinylpyrrolidone is used as a solubilizer in oral and parenteral formulations 
and has been shown to enhance dissolution of poorly soluble drugs from solid-
dosage forms. Polyvinylpyrrolidone solutions may also be used as coating 
agents. 
 
 Polyvinylpyrrolidone is additionally used as a suspending, stabilizing, or 
viscosity increasing agent in a number of topical and oral suspensions and 
solutions.  
 
 The solubility of a number of poorly soluble active drugs may be increased by 
mixing with Polyvinylpyrrolidone. 
 
 Uses of Polyvinylpyrrolidone. 
 Carrier for drugs   
 Dispersing agent  
Chapter – VIII                                       POLYMERS AND EXCIPIENTS PROFILE 
 
Madurai Medical College Page 79 
 
 Eye drops  
 Suspending agent  
 Tablet binder, tablet diluent, or coating agent  
 
Description 
 Polyvinylpyrrolidone occurs as a fine, white to creamy-white colored, odorless 
or almost odourless, hygroscopic powder. 
 Polyvinylpyrrolidone with K-values equal to or lower than 30 are manufactured 
by spray-drying and occur as spheres. 
 Polyvinylpyrrolidone K-90 and higher K-value Polyvinylpyrrolidone are 
manufactured by drum drying and occur as plates. 
 
Solubility: 
                  Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water; practically insoluble in ether, hydrocarbons, and mineral oil. In water, the 
concentration of a solution is limited only by the viscosity of the resulting solution. 
 
Stability and Storage Conditions 
 
               Polyvinylpyrrolidone may be stored under ordinary conditions without 
undergoing decomposition or degradation. However, since the powder is hygroscopic, it 
should be stored in an airtight container in a cool, dry place. 
 
Incompatibilities 
 
 Polyvinylpyrrolidone is compatible in solution with a wide range of 
inorganic salts, natural and synthetic resins, and other chemicals.  
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 It forms molecular adducts in solution with sulfathiazole, sodium 
salicylate, salicylic acid, phenobarbital, tannin, and other compounds. 
Safety 
 
                Polyvinylpyrrolidone is widely used as an excipient, particularly in oral 
tablets and solutions (Raymond C et al., 2006). When consumed orally, 
Polyvinylpyrrolidone may be regarded as essentially nontoxic since it is not absorbed 
from the gastrointestinal tract or mucous membranes. 
 Polyvinylpyrrolidone additionally has no irritant effect on the skin and causes 
no sensitization. 
 
Handling Precautions 
 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection, gloves, and a dust mask are recommended. 
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CHAPTER-IX 
EXPERIMENTAL DETAILS 
 
I. CALIBRATION OF PERINDOPRIL ERBUMINE: 
a) Preparation of dissolution medium: 
  0.1M Hydrochloric Acid: 
                            Dilute 8.5 ml of hydrochloric acid in distilled water and the volume is made 
up to 1litre   
b) Calibration Curve of Perindopril Erbumine: 
                           To the powder containing 10mg of Perindopril Erbumine, 10ml of distilled 
water is added and the volume is made up to 100ml with 0.1M hydrochloric acid. Dilutions 
are made to get the concentration of 5 to 50µg/ml.  10µg/ml solution is scanned in (UV) 
Spectrophotometer to find out the λmax and absorbance is measured at the obtained λmax 
(208nm). The calibration graph is plotted by taking the concentration on X axis and 
respective absorbance in Y axis, to get a straight line as per like Beers law. The regression 
value is determined. 
II. PREFORMULATION (COMPATABILITY) STUDIES: 
 
a) Differential Scanning Colorimetric studies (DSC): 
                 DSC is performed using Q 200 V24.4 thermal analyzer. The instrument is 
calibrated with indium standard. Accurately weighed (it varies from 3mg -25mg) samples 
are placed in an open type ceramic sample pans. Thermo grams are obtained by heating the 
Chapter-IX                                                                     EXPERIMENTAL DETAILS 
 
Madurai Medical College Page 82 
 
sample at a constant heating rate of 8˚C/minute. A dry purge of argon gas (60ml/min) is 
used for all runs. Samples are heated from 37˚-400˚C. 
b) Fourier Transform-Infra Red (FT-IR) Studies:  
                    The possibility of drug–excipients interactions are further investigated by FT-
IR. The FT-IR graph of pure drug and combination of drug with excipients are recorded. 
The analysis is performed by using (shimadzu FT-IR, Japan) spectrometer. The scanning 
range is 450-4000 cm-1 and the resolution is 4 cm-1 sample is prepared in KBr pellets. 
 
III. PREPARATION OF FLOATING MICROSPHERS: 
                       Floating microspheres are prepared by using water-in-oil-in-oil (w/o/o) 
double emulsion solvent diffusion method (K. Rama Rao et al., 2005, Bipul Nath et al., 
2010) using different rations of polymers to drug. The polymers is composed of Ethyl 
cellulose (F1-F4), Ethyl cellulose with Hydroxyl Propyl Methyl Cellulose (F5-F8), ethyl 
cellulose With Polyvinyl Pyrrolidine K30 (F9-F12), ethyl cellulose with Eudragit S 100 
(F13-F16), and ethyl cellulose with Polyvinyl Pyrrolidine K90 (F17-F20). Briefly drug and 
polymer mixture are dissolved in the mixed solvent system consisting of Acetone and 
Dichloromethane  in a1:1 ratio for  F1 to F8, Acetone, Ethanol and Dichloromethane in a 
1:1:1 ration for F9 to F12 and F17 to F20, Ethanol, Isopropyl alcohol and Dichloromethane 
(Yuveraj Singh et al.,2007) in a 1:1:1 ratio for F13 to F16.  
The initial w/o emulsion is prepared by adding 4ml of water to the drug-polymer 
solution while stirring using a mechanical stirrer (lab stirrer, Remi motors, India) at 500 
rpm for 5 min. This w/o primary emulsion is slowly added to 200ml (V.S Mastiholimath et 
al., 2008) of light liquid paraffin, the second a oil phase containing 0.1% span80 as a 
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surfactant while stirring at 1000 rpm. After  2 h, 10ml of cyclohexane (non solvent) is 
added to harden the microspheres and the stirring is continued for a further 1 h and the 
hardened microspheres are collected by filtration and washed with three portions of 50ml 
of cyclohexane and air dried for 12 h. Table     ( 2) shows the composition of various 
prepared floating microspheres formulations. 
IV. CHARACTERIZATION OF FLOATING MICROSPHERES 
a) Percentage Yield: 
                            The yield percentage of the produced microspheres is (A.H.EL-Kamel et 
al., 2001; Pratim.K Choudhury & Mousumi Kar 2009) calculated for each batch by 
dividing the whole weight of product (M) by the total expected weight of drug and polymer 
(Mo)   
                                                        Weight of microspheres (M) 
Percentage yield     =     ---------------------------------------------------------------------     x 100 
                                           Total expected weight of drug and polymer (Mo)  
 
b) Particles Size Analysis 
                                  Particle size distribution is analyzed by (V.S Mastiholimath et al., 
2008) placing of the formulated microspheres in a set of standard test sieves and shaking it 
for a particular time interval. The particles collected in each sieve were weighed and the 
percentage particles retained on each sieve was calculated. The average diameter of the 
microspheres is represented by the geometric mean diameter obtained. 
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c) Drug Entrapment Efficiency: 
The amount of perindopril erbumine present in the microspheres is determined by 
extracting into acid buffer (0.1M hydrochloric acid). Microspheres (Pratim.K Choudhury & 
Mousumi Kar 2009) are crushed and powdered by using a mortar and pestle and accurately 
weighed amount of this powder is extracted into 100ml of acid buffer (0.1M hydrochloric 
acid) by stirring at 1000 rpm for 2 h. The solution is filtered; suitable dilutions are made 
and estimated for perindopril erbumine content spectrophotometrically at 208 nm. 
            Theoretical drug loading in microspheres is estimated by using (M.saravanan, B. 
Anupama2011; Pratim.K Choudhury & Mousumi Kar 2009) the following formula 
             Weight of drug 
           Theoretical drug loading (%) = --------------------------------------   x 100 
                    Weight of microspheres 
 
                                  The Entrapment efficiency of prepared microspheres is calculated by 
using  
(Malaykumar et al., 2006; Chudiwal P.D et al., 2009; Pandey Manisha et al., 2010) the 
following formula   
                                                             Experimental drug content 
Entrapment efficiency (%)   =   --------------------------------------------   x 100 
                                                          Theoretical drug content 
 
d) In-Vitro Percentage Buoyancy Studies: 
                         The floating microspheres (300mg) are spread over the surface of the 
dissolution medium (simulated gastric fluid pH 1.2) containing Tween 20 (0.02% w/v) that 
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is agitated by a paddle rotated at 100 rpm (R.B.Uma maheswari et al., 2003; V.S 
Mastiholimath et al., 2008). After agitation for a predetermined time interval, the 
microspheres that floated over the surface of the medium and those settled at the bottom of 
the jar are recovered separately. After drying, each fraction of the microspheres is weighed 
and the buoyancy of the microspheres if calculated by the following equation: 
                                            Percentage Buoyancy = Qf / (Qf + Qs) 
 
Where Qf and Qs are the weight of the floating and the settled microspheres, respectively. 
 
e) In-vitro Release Studies: 
In vitro release studies are performed in USP type II paddle (V.S.Mastiholimath et 
al., 2008; Ghodake J.D.et al., 2010; S.Sungthonjeen et al., 2006) apparatus for 12 hours. 
The microspheres are placed in the dissolution medium of 900ml 0.1M hydrochloric acid in 
the dissolution apparatus. The paddle is rotated at 100 rpm maintained at 37˚C. 5ml 
samples are withdrawn every 15 min for the first hour and every 30 min up to 11 hours. 
Sink conditions are maintained after each sampling. Samples are analyzed at 208 nm using 
UV spectrophotometer. The studies are done in triplicate. 
 
f) Kinetic Analysis: 
The in-vitro release profiles obtained from the floating microspheres are (Paulo 
Costa et al.,2001) fitted to zero order, first order, Hixson Crowell, Korsemeyer & peppas 
model kinetics, to find out the mechanism of drug release. 
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Zero order                                          :                     Qt = Qo + Ko.t 
First order                                          :                      In Qt = In Qo + Ko.t 
Hixson-Crowell                                 :                      Qo1/3 – Qt1/3 + K.t 
Higuchi                                              :                       Q = KH.t1/2 
Korsmeyer- peppas                            :                       Mt/Mo = a.tn 
                      Fitness of release profiles to linear equations is assessed by comparing the 
coefficients of determination (r) values.  
For cylinder type of systems (Paulo Costa et al., 2001), 
n<0.5                                                : classical Fickian diffusion 
n=0.5to1.0                                        : anomalous Non Fickian transport i.e. coupled drug 
 diffusion in the hydrated matrix and polymer             
relaxation (Indicators of both phenomenons) 
n=1.0                                                : case II relaxational release transport – zero order  
                                                           release (Polymer relaxation or swelling controlled 
                                                            systems) 
n > 1.0                                             : super caseII transport. 
 
V. SELECTION OF BEST FORMULATION 
                    The best formulation is selected depending on the results obtained from  
 Percentage yield 
 Entrapment Efficiency 
 Percentage buoyancy 
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 In-vitro Release Studies 
 Release kinetics. 
a) EVALUATION OF BEST FORMULATION 
The selected best formulation is subjected to, 
1. X-Ray diffraction studies 
2. Scanning Electron Microscopy (SEM) analysis 
3. In-vivo X-Ray studies 
 
 
1) X-Ray Diffraction Studies: 
 Perindopril erbumine, perindopril erbumine loaded Ethyl cellulose/HPMC 
microspheres , physical mixture of perindopril erbumine and ethyl cellulose/HPMC are 
subjected to X-ray diffraction study in an X-ray diffractometer (XD, Shimadzu, Japan) 
within the range 10-80˚ of 2θ (Yuanfen Liu et al., 2011). 
2) Scanning Electron Microscopy (SEM): 
                    Scanning electron microscopy (SEM) studies are performed (Garg and Gupta, 
2010) to determine the porous/ hollow nature of the microspheres. Surface morphology of 
microspheres is also noted. 
3) In-Vivo X- Ray Studies: 
                  The in-vivo studies approved by institutional animal ethical committee reference 
No.14024/E1/4/2011 and are performed on healthy male albino rabbit weighing 2-3 kg. 
The animal is fasted overnight but allowed to take water libitum. Then 60ml of 5% 
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dextrose solution is given immediately before administering the microspheres by using 
stomach tube (NO.12French catheter) and 50ml syringes.        
               The microspheres are made opaque by incorporating Barium sulphate (BaSO4) 
instead of drug. The rabbit is exposed to X-ray imaging in the abdominal region, and 
photographs are taken at 0, 4, 8, 12 hrs after administration of microspheres. At hourly 
intervals 60 ml of 5% dextrose solution is given to maintain optimum fluid level in the 
stomach. The gastric residence time is observed. 
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CHAPTER-X 
RESULTS AND DISCUSSION 
I. CALIBRATION OF PERINDOPRIL ERBUMINE:  
The λmax of perindopril erbumine was determined by scanning the 10 µg/ml 
solution of the drug using UV spectrophotometer and was found to be 208nm is shown 
in Fig:14 (European Pharmacopoeia 2009).The absorbance of the solutions (5 – 50 
µg/ml) was measured in UV spectrophotometer at 208 nm. The correlation coefficient 
was found to be γ = 0.99985.  The results were given in Table: 1 and the calibration 
graph of perindopril erbumine were shown in Fig: 15 
II. PREFORMULATION (COMPATABILITY) STUDIES: 
a) Differential Scanning Colorimetric Studies (DSC):
 
 The DSC thermo grams of pure drug and the different polymers were shown in 
the Fig.16 an endothermic peak corresponding to the melting point of pure drug was 
important in all the drug polymer mixture, which suggested clearly that there was no 
interaction between the drug and the polymers and the drug was existed in its 
unchanged form. 
b) Fourier Transform-Infra Red(FT-IR) Studies: 
             FT-IR spectrum of the drug and polymers are shown in the fig.17 The spectrum 
of the drug had characteristic peaks of C-H stretching (VF 2929, 2848, 2750), C=O 
stretching (VF 2640&1739 cm
-1
), hydrogen bonded acids (VF 2551.61 cm
-1
), C-H 
bending (VF 1392 cm
-1
), OH bending (VF 1315, 1292, 1205 cm
-1
), aromatic rings (VF 
1566 cm
-1
), C-H rocking (939, 750, 703, 475 cm
-1
) thus indicating the identity and 
purity of the drug. 
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All those characteristic peaks were also found in the spectrum of drug and 
polymer combinations and there was no change in the existing peaks. This clearly 
indicated that there was no interaction between the drug and the polymer and the drug 
was present in its unchanged form.   
 
III. PREPARATION OF FLOATING MICROSPHERES: 
Floating microspheres were prepared by using water-in-oil-in-oil(w/o/o) double 
emulsion solvent diffusion method(K.Rama Rao et al.,2005, Bipul Nath et al.,2010), 
using different ratio of mixed polymers to perindopril erbumine.Table (2) shows the 
composition of various prepared floating microspheres formulations. The perindopril 
erbumine and polymer (Ethyl cellulose) was in the ratio of 1:1, 1:2, 1:3 and 1:4 for F1, 
F2, F3 and F4 respectively,Perindopril Erbumine and mixed polymer(Ethyl cellulose 
with HPMC) in the ratio of 1:1, 1:2, 1:3 and 1:4 for F5, F6, F7 and F8 
respectively,Perindopril Erbumine and mixed polymer(Ethyl cellulose with PVP K30) in 
the ratio of 1:1, 1:2, 1:3 and 1:4 for F9, F10, F11 and F12 respectively,Perindopril 
Erbumine and mixed polymer(Ethyl cellulose with Eudragit S100)in the ratio of 1:1, 
1:2, 1:3 and 1:4 for F13, F14, F15 and F16 respectively andPerindopril Erbumine and 
mixed polymer(Ethyl cellulose with PVP K90) in the ratio of 1:1, 1:2, 1:3 and 1:4 for 
F17, F18, F19 and F20 respectively. 
The  preparation of  microsphere was carried out by emulsifying an aqueous 
solution in to solution of drug and polymers in mixed solvent system comprising of 
Acetone and dichloromethane in equal volume for  F1 to F8, Acetone ,Ethanol and 
Dichloromethane  in equal volume for F9 to F12 and  F17 to  F20, Ethanol, Isopropyl 
alcohol and Dichloromethane in equal volume for F13 to F16, followed by 
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emulsification of this  primary emulsion (w/o) in to an external oil phase (liquid 
paraffin) to form a water in oil in oil (w/o/o) emulsion. 
  Microspheres were formed after a series of steps like solvent extraction, solvent 
evaporation and addition of a non-solvent.The solvents of the system were removed by a 
combination of extraction and evaporation. It is very important to carefully select the 
solvent combination and processing medium to enable the formation of double emulsion 
and solvent extraction and evaporation by a combination. 
Acetone is a unique organic solvent which is polar, water miscible and oil 
immiscible and dichloromethane is non polar and oil miscible (Badri viswanathanet al. 
1999) so, during the formation of microspheres dichloromethane was extracted by liquid 
paraffin and acetone was evaporated during stirring. 
Each step of microsphere preparation was intensely observed to understand the 
effect of particle size, total entrapment and release profile of the drug loaded 
microspheres. After introduction of w/o primary emulsion in to liquid paraffin, the 
emulsion was stirred for 2 hr using mechanical stirrer (Remi lab stirrer), during this 
phase it is assumed that the droplet sizes were allowed to stabilize while some amount of 
dichloromethane and acetone escaped, making the emulsion droplets become more 
viscous. 
The cyclohexane, non solvent for the polymer added at this stage might have 
caused the quick precipitationof the polymer leaving the surface of microspheres porous 
in nature.No surfactant was used for stabilizing w/o primary emulsion because ethyl 
cellulose itself acts as a surfactant(Melzer et al.,2003). Span 80 (sorbitan monooleate) 
was used to stabilise the secondary emulsification process. 
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IV. CHARACTERIZATION OF FLOATING MICROSPHERES 
a) Percentage Yield: 
The percentage yield of produced floating microspheres was shown in Table: 4. 
Increasing the polymer concentration lead to subsequent increase in its 
hydrophobicityconsequently, it will react better with non solvent phase (liquid paraffin) 
leading to more efficient precipitation of the polymer at the droplet interface with 
subsequent higher yield. 
Increasing polymer ratio in the formulation led to increase the product yield 
(S.Sehra&A.S.Dhake., 2005).The low percent yield in some formulations may also due 
to microspheres lost during successive decantation during washing process. 
b) Particle Size Analysis 
Formulation F4(1:4), F8(1:4), F12(1:4), F16(1:4) and F20(1:4) showed relatively 
larger particle size and formulation F1(1:1), F5(1:1), F9(1:1), F13(1:1) and F17(1:1) 
showed relatively small particle size of floating microspheres.  
The polymer to drug ratio appears to influence the particle size distribution of floating 
microspheres (K.Rama Rao et al., 2005), as shown in Tables: 4. 
When the polymer to drug ratio was increased, the proportion of larger particles was 
high, because the viscosity of the primary emulsion was increased with increase of 
polymer to drug ratio. Due to this increased viscosity, large emulsion droplets were 
formed and it was difficult to break them and, hence, they were precipitated as such 
leading to an increase in the mean particle size of floating microspheres, as shown in 
Table: 4. 
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c) Drug Entrapment Efficiency: 
Drug entrapment efficiency was found to be 84.10%, 88.29%, 91.58%,95.97%, 
85.98%, 88.29%, 93.45%, 95.79%, 66.35%, 77.25%, 79.43%, 93.45%, 67.28%, 
68.69%, 78.50%, 86.44%, 71.02%, 78.51%, 91.56% and95.75% for formulation 
F1(1:1), F2(1:2), F3(1:3), F4(1:4), F5(1:1), F6(1:2), F7(1:3), F8(1:4), F9(1:1), F10(1:2), 
F11(1:3), F12(1:4), F13(1:1), F14(1:2), F15(1:3), F16(1:4), F17(1:1), F18(1:2), 
F19(1:3)andF20(1:4)respectively. 
Among the different drug polymer ratios investigated 1:4 (F4, F8, F12, F16, and F20)    
drug-polymer ratio had the maximum capacity for drug entrapment as shown in Figure: 
18. 
Drug entrapment efficiency was increased with increasing polymer concentration in 
floating microspheres (Pratim.K Choudhury & Mousumi Kar 2009, Pandey Manisha et 
al., 2010,) as shown in Tables: 4. 
Reason for High Entrapment Efficiency: 
As the high molecular weight of the polymer (Ethyl cellulose) increased its 
hydrophobicity increased, leading to better precipitation of the polymer at the boundary 
phase of the droplets (M.S.Uddinet al.,2001). Consequently, partitioning of drug to the 
continuous phase (liquid paraffin) will be minimal. 
Thehigher entrapment of the perindopril erbumine to the polymer blend (Ethyl 
cellulose with HPMC) may be attributed to faster precipitation of polymer at sphere 
interface at this drug: polymer (1:4) ratio, consequently, higher amount of drug was 
entrapped. 
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d) In-vitro Percentage Buoyancy Studies: 
The buoyancy percentage for all batches was almost above 60% (Fig 19), which was 
studied for 12hrs, in dissolution medium (simulated gastric fluid pH 1.2) containing 
Tween 20 (0.02% w/v) without enzymes. The average buoyancy in percentage was 
found to be 62.06% to 82.77%. The highest percentage was obtained with formulation 
F4 (1:4), F8 (1:4), F12 (1:4), F16 (1:4) and F20 (1:4). In general with increase in the 
amount of polymer blend (Ethyl cellulose + HPMC), there was an increased in 
buoyancy percentage (Pandey Manisha et al., 2010). From the Table: 4 it was concluded 
that on increasing polymer concentration simultaneously percentage buoyancy also 
increased.  
e) In-Vitro Release Studies: 
The cumulative percentage drug release after 12 hr was found to be 80.83%,74.70%, 
65.98% and 66.63% for the formulations of  F1 to F4, 82.24%, 76.26%, 74.56% and 
68.13% for the formulations of F5 to F8, 77.78%, 72.65%, 71.68% and 69.49% for the 
formulations of F9 to F12, 82.11%, 73.30%, 72.86% and 70.12% for the formulation of 
F13 to F16 and 86.95%, 78.05%, 73.36% and 66.84% for the formulation of  F17 to 
F20. It was found that the drug release was prolonged up to 12 hrs.The results are shown 
in figure 21, 21, 22, 23, & 24. It was also observed that as the polymer ratio increased 
the drug release was decreased (V.S.Mastiholimath et al., 2008). 
The in-vitro release of perindopril erbumine from floating microsphere was biphasic 
with the initial burst effect which was varied from 15% to 27% depending on the 
polymer-to-drug ratio (K.Rama Rao et al., 2005). The initial burst effect was due to 
presence of drug particle on the surface of the microspheres, which was exposed by 
scanning electron microscope studies. 
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The initial burst effect may also attribute as a desired effect to ensure initial high 
plasma concentration of drug to produce pharmacological action. In order to keep the 
total surface area of the microsphere constant. The effect of retardation on the release 
rate depends on the polymer to drug ratio. As the concentration of polymer increased 
with respect to drug which may be attributed to the slower rate of diffusion of 
dissolution medium into the microspheres due to increased density of the polymer 
matrix at higher concentration result in an increased diffusional path length. This may 
decrease the overall drug release from the polymer matrix.  
After the total drug release (12hr) the floating microspheres were collected and 
observed under SEM for the surface change occurred after dissolution. Furthermore, 
smaller floating microspheres were formed at a lower polymer concentration and have a 
longer surface area exposed to dissolution medium, giving rise to faster drug release. 
f) Kinetic Analysis: 
The in-vitro release profile was applied on various kinetic models in order to find 
out mechanism of drug release. The correlation coefficient of F1 to F20 formulations for 
zero order, Higuchi, Hixon-crowell and first order equations was shown in Table: 5. 
Formulation F8 was found high correlation to zero order kinetics (0.987, Figure: 25) as 
well as Higuchi plot (0.997, Figure: 26) rather than Hixson-crowell models. 
The drug release was proportional to square root of time, indicating that the drug 
release from polymeric (EC+HPMC) microspheres was diffusion controlled. The data 
obtained was also put in Korsemeyer-peppas equation in order to find out n value (0.506 
to 0.726 for F1 to F20), which describes the drug release mechanism by Non Fickian 
diffusion. 
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V. SELECTION OF BEST FORMULATION: 
From the above results of characterization F8 was selected as the best 
formulation because, 
 Percentage yield  :76.84% 
 Entrapment efficiency  :95.79% 
 Percentage buoyancy  :82.77% 
 Cumulative % drug release :68.13% 
 Release kinetics  :closest linearity to zero order kinetics, 
Higuchi model and Non-Fickian diffusion 
mechanism   
 
a) EVALUATION OF BEST FORMULATION 
The selected best formulation F8 was subjected to, 
1. X-Ray diffraction studies 
2. Scanning Electron Microscopy (SEM) analysis 
3. In-vivoX-Raystudies 
 
1) X-Ray Diffraction Studies: 
In order to determine the physical state of the drug whether amorphous or crystalline 
before and after floating microspheres formulation, X-ray examination were conducted 
for the pure drug, the polymer mixture and the formulations of floating microspheres 
(Figure: 28).From X-ray patterns it was obvious that the pure drug exhibited crystalline 
characteristics peaks, polymers exhibited amorphous pattern while formulations showed 
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reduced crystallinity peaks of pure drug.  
The amorphous state of spheres releases the drug less rapidly than the crystalline 
spheres (S.Freiberg and X.X.Zhu., 2004).Therefore, the lack of polymer crystallinity 
suggests betterdrug dispersion and increased drug polymer interactions. The drug release 
rate can be tailored by manipulating the degree of crystallinity; reduced crystallinity is 
favourable when slow release is desired. 
2) Scanning Electron Microscopy (SEM):  
Scanning electron microscopy(SEM) exposed the distinct, spherical shaped spheres 
with rough surface and presence of holes /hollow cavity due to the collapse of the wall 
of the microspheres during in situ drying process (Gangadharappa H. V et al., 2011). 
Thus the rate of solvent removal from the embryonic microspheres exerts an influence 
on the morphology of the end product. 
 Porous structure was observed on the surface of microspheres shell due to the rapid 
diffusion of the solvent, there is a possibility of rupture of some microspheres. 
Microspheres floated more than 12 h because of presence of pores. SEM photographs 
were shown in Figure: 29 and 30. 
3) In-Vivo X-Ray Studies: 
The in vivo floating behaviour of microspheres loaded with barium sulphate was 
investigated by radiographic images (X- ray photographs) of rabbit’s stomach at specific 
periods.  
The amount of X-ray opaque material in these microspheres was sufficient to ensure 
visibility by X-ray but at same time the amount of barium sulphate (100 mg) was low 
enough to enable the microspheres to float(Gangadharappa H. V et al., 2011). 
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The floatingmicrospheres did not adhere to the gastric mucous and floating on the 
gastric fluid for about more the 12 h. This was evident by the X-ray photographs taken 
at 0 hr, 4
th
 hr, 8
th
 hr& 12
th
 hr. It was shown in Figure: 31. 
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Table 1:  Calibration of Perindopril Erbumine 
 
 
Medium : 0.1M HCL  
λ max  : 208 nm 
 
S. No. CONCENTRATION  
(µg/ml) 
ABSORBANCE 
* 
STANDARD DEVIATION  
*  (± S.D) 
1. 5 0.108 0.005 
2. 10 0.230 0.017 
3. 15 0.338 0.009 
4. 20 0.457 0.018 
5. 25 0.564 0.012 
6. 30 0.684 0.017 
7. 35 0.784 0.023 
8. 40 0.903 0.009 
9. 45 1.002 0.028 
10.  
50 1.119 0.022 
 
R
2
 Value =         0.99985 
* Average of three trial 
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Table 2: Formulation Table for Floating Microspheres of Perindopril Erbumine 
 
 
Formulation 
code 
 
Drug: 
Polymer 
 
Liquid 
Paraffin 
(ml) 
 
Drug (gm) 
 
Ethyl 
cellulose 
(gm) 
 
HPMC (gm) 
 
PVP K30 
(gm) 
 
Eudragit 
S100 (gm) 
 
PVP K90 
(gm) 
F1 1:1 200 0.5 0.500 - - - - 
F2 1:2 200 0.5 1.000 - - - - 
F3 1:3 200 0.5 1.500 - - - - 
F4 1:4 200 0.5 2.000 - - - - 
F5 1:1 200 0.5 0.250 0.250 - - - 
F6 1:2 200 0.5 0.750 0.250 - - - 
F7 1:3 200 0.5 1.250 0.250 - - - 
F8 1:4 200 0.5 1.500 0.500 - - - 
F9 1:1 200 0.5 0.250 - 0.250 - - 
F10 1:2 200 0.5 0.750 - 0.250 - - 
F11 1:3 200 0.5 1.250 - 0.250 - - 
F12 1:4 200 0.5 1.500 - 0.500 - - 
F13 1:1 200 0.5 0.250 - - 0.250 - 
F14 1:2 200 0.5 0.750 - - 0.250 - 
F15 1:3 200 0.5 1.250 - - 0.250 - 
F16 1:4 200 0.5 1.500 - - 0.500 - 
F17 1:1 200 0.5 0.250 - - - 0.250 
F18 1:2 200 0.5 0.750 - - - 0.250 
F19 1:3 200 0.5 1.250 - - - 0.250 
F20 1:4 200 0.5 1.500 - - - 0.500 
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Table - 3 
In-Vitro Release Profile of Perindopril Erbumine Floating Microspheres 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F1 (D:P 1:1) F2 (D:P 1:2) F3 (D:P 1:3) 
Mean ±SD Mean ±SD Mean ±SD 
0.25 12.393 1.883 11.540 2.797 6.487 1.063 
0.5 16.896 1.157 18.433 0.825 11.284 0.787 
0.75 21.656 0.274 21.000 0.749 13.096 0.510 
1 25.943 1.258 24.110 0.545 15.790 0.515 
1.5 28.926 0.482 26.966 0.350 17.799 0.269 
2 32.126 1.603 29.730 0.465 20.353 0.313 
2.5 34.833 0.249 32.073 0.550 21.922 0.507 
3 38.536 2.255 35.416 0.600 23.505 0.271 
3.5 39.796 0.778 38.270 0.574 25.441 0.517 
4 41.846 1.321 40.516 0.591 26.233 0.502 
4.5 43.533 2.525 43.013 0.748 28.493 1.010 
5 47.503 0.814 45.646 0.531 30.851 0.515 
5.5 50.707 0.754 47.083 0.510 33.044 1.20 
6 53.426 0.440 46.946 1.610 35.370 0.832 
6.5 56.560 0.618 51.280 1.589 39.256 0.541 
7 57.546 1.051 54.560 1.309 41.868 0.543 
7.5 59.146 0.507 56.723 3.136 43.980 0.786 
8 62.450 3.495 58.646 2.514 44.611 1.665 
8.5 67.843 1.583 61.746 1.737 46.894 1.367 
9 70.456 1.650 63.733 1.753 48.897 0.840 
9.5 71.873 0.649 66.723 1.046 50.393 1.219 
10 73.990 1.463 68.543 1.729 54.287 0.950 
10.5 76.336 1.033 71.716 0.918 56.020 0.967 
11 78.276 1.516 71.983 0.666 58.255 0.642 
11.5 80.473 1.153 73.400 1.140 60.657 0.885 
12 80.830 0.921 74.700 0.459 65.968 0.439 
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Table – 3a 
In Vitro Release Profile of Perindopril Erbumine Floating Microspheres 
 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F4 (D:P 1:4) F5 (D:P 1:1) F6 (D:P 1:2) 
Mean ±SD Mean ±SD Mean ±SD 
0.25 5.625 1.546619 11.3625 1.0125 11.7375 2.571144 
0.5 12.8125 0.735335 14.71375 0.760048 14.23083 1.267969 
0.75 14.97917 0.742995 17.57583 0.81698 17.0875 1.097124 
1 17.84333 0.516366 21.29292 0.584883 19.29917 0.799446 
1.5 20.55 0.518623 24.56167 1.573119 20.33333 1.42111 
2 22.27208 1.030043 27.37667 2.054021 22.38917 0.990835 
2.5 23.18583 0.594645 27.3325 1.915728 24.16542 0.501841 
3 24.81958 0.92565 30.17208 0.591091 25.77125 0.802632 
3.5 27.29375 0.364865 33.49 1.053218 27.39208 0.802944 
4 29.905 0.473483 34.89125 0.471671 28.87792 0.800212 
4.5 31.75458 0.875049 36.75417 0.465833 30.86458 0.444438 
5 34.25875 1.340195 38.06 0.989207 31.52 0.3675 
5.5 36.63708 0.801224 39.73613 1.132155 33.67917 0.70902 
6 38.85042 1.020595 41.82779 1.159991 35.37125 0.530729 
6.5 40.25917 1.074487 45.03321 0.983941 37.26583 0.528894 
7 41.86667 0.396521 47.05454 0.608796 39.14 0.541808 
7.5 43.4875 0.350475 49.73829 1.353056 40.69333 0.644765 
8 45.90917 0.661369 52.59571 1.431443 42.97208 0.553513 
8.5 47.90292 0.87578 56.51871 1.884152 44.93417 0.551561 
9 51.22625 1.599676 60.15496 1.131806 47.21333 0.859706 
9.5 53.08125 0.932814 62.58788 1.631339 49.85042 1.073261 
10 55.13875 0.596884 65.90371 0.989954 53.89917 1.448386 
10.5 57.02583 0.889507 68.91204 1.893726 57.95 0.999629 
11 58.92792 0.857519 72.09663 1.403315 62.115 1.104165 
11.5 60.17 2.045867 77.10913 0.549071 69.2825 1.284288 
12 63.63208 1.24939 82.24454 0.11861 76.26042 0.839038 
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Table – 3b 
In Vitro Release Profile of Perindopril Erbumine Floating Microspheres 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F7(D:P 1:3) F8(D:P 1:4) F9 (D:P 1:1) 
Mean ±SD Mean ±SD Mean ±SD 
0.25 11.4 0.507291 6.15 2.424194 9.1875 2.041599 
0.5 13.55167 0.509489 12.29333 0.822168 14.20208 1.259966 
0.75 16.02583 0.589314 14.79167 1.436209 17.54625 0.826284 
1 19.08833 0.762185 18.17875 1.10406 20.92583 1.022049 
1.5 20.64542 0.529101 20.36417 0.555572 23.02833 0.842134 
2 23.905 0.523038 22.49667 0.611305 26.16417 1.097106 
2.5 25.17333 0.528669 24.08792 1.061456 28.61958 0.862559 
3 26.94042 1.03779 25.69417 0.647102 31.62417 1.386895 
3.5 28.76167 0.929286 27.61542 1.388316 34.65875 1.391016 
4 30.6 0.551403 29.5925 0.82516 38.21083 1.64748 
4.5 32.75542 0.245949 32.26333 0.532703 41.01083 0.916565 
5 34.25625 1.063249 33.94792 1.329334 44.1 0.701574 
5.5 34.6075 1.031223 35.985 0.608134 44.89375 1.519839 
6 37.17125 0.813819 38.04083 0.433246 48.24125 0.633765 
6.5 39.57208 0.79889 40.26542 1.123544 48.92083 1.168885 
7 41.65792 0.878196 41.53542 0.315011 48.59 0.481205 
7.5 43.6125 0.837149 43.64 0.628126 49.7125 0.490453 
8 47.75917 0.409276 45.42583 0.920096 51.55458 1.166697 
8.5 49.05958 0.18657 46.88917 0.92895 53.08542 0.652112 
9 55.95667 1.605639 49.03875 0.651254 55.28013 0.409143 
9.5 57.525 2.122337 51.05708 0.991026 56.67971 0.830501 
10 60.82958 0.630993 53.5425 1.171762 60.93888 0.624293 
10.5 63.41458 1.341159 56.275 1.787773 67.30179 4.292064 
11 68.75917 1.624908 59.51958 1.677128 69.90388 0.710502 
11.5 72.95625 1.132812 63.46917 0.956174 74.29013 1.299974 
12 74.5675 1.406986 68.13125 0.935784 77.78013 1.227609 
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Table – 3c 
In Vitro Release Profile of Perindopril Erbumine Floating Microspheres 
 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F10 (D:P 1:2) F11 (D:P 1:3) F12 (D:P 1:4) 
Mean ±SD Mean ±SD Mean ±SD 
0.25 7.1625 1.804681 6.825 1.856534 8.1 1.14175 
0.5 13.50458 1.779342 14.32583 1.252112 12.84083 0.333158 
0.75 16.65375 1.020694 17.18417 0.528368 16.17 0.498549 
1 20.73625 0.795378 16.9975 4.59429 17.88458 0.50567 
1.5 22.98708 0.804243 19.73167 1.2035 19.91625 0.271733 
2 25.93542 1.80723 21.81917 0.540012 22.15583 1.031917 
2.5 26.55125 1.937434 23.74 0.376889 23.74292 0.743759 
3 28.33333 1.606949 25.34208 0.560186 25.195 0.749741 
3.5 30.50708 0.826908 27.48417 1.125247 26.62292 1.800435 
4 32.70167 0.449549 30.13458 0.871343 28.58875 1.642586 
4.5 34.54208 0.537623 31.42375 1.249402 30.57333 1.082585 
5 36.77417 0.794396 33.28625 0.843915 32.08917 0.518562 
5.5 37.63958 1.222985 35.50333 0.608324 34.25583 1.101449 
6 40.38542 1.073985 38.37875 0.587145 36.48042 1.311715 
6.5 43.1575 0.578418 41.13208 0.344783 37.86333 1.325541 
7 45.28083 0.836303 43.23667 0.396883 39.745 1.148176 
7.5 47.08542 1.009644 44.8725 0.204393 42.01833 1.624407 
8 49.2425 0.855686 44.79667 1.764035 43.9375 1.43792 
8.5 51.41833 1.160954 47.0775 0.94575 45.87333 1.881417 
9 53.61292 1.038901 49.41625 0.171469 48.53833 1.201989 
9.5 56.16375 0.631977 50.76333 0.184706 51.22792 2.176612 
10 58.54958 0.728992 52.7575 0.416719 53.90333 2.041307 
10.5 60.73083 0.462941 55.14333 0.468362 58.16792 1.918457 
11 64.13 0.946203 59.2 0.486486 62.11167 2.484164 
11.5 69.13542 0.660611 64.60833 2.397258 65.60542 2.925142 
12 72.65208 0.941215 71.68292 0.628617 69.46875 0.367553 
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Table – 3d 
In Vitro Release Profile of Perindopril Erbumine Floating Microspheres 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F13 (D:P 1:1) F14 (D:P 1:2) F15 (D:P 1:3) 
Mean ±SD Mean ±SD Mean ±SD 
0.25 9.493333 2.600276 14.98 0.52144 14.17 1.102588 
0.5 11.95333 2.362717 15.69333 0.793872 15.03333 1.368442 
0.75 14.95333 1.199264 17.81667 1.068285 17.03667 1.605314 
1 17.65 1.998274 18.24667 1.26263 18.42 0.536936 
1.5 19.86667 0.851724 19.35333 1.143431 19.65667 0.411987 
2 21.92333 1.576843 20.55667 0.688791 21.34667 0.930287 
2.5 24.03 0.904212 22.20667 0.677963 22.81333 1.298666 
3 25.56333 1.167576 22.52 1.230894 23.93667 1.459086 
3.5 27.98333 2.888968 24.60333 0.811316 25.88667 0.786914 
4 28.36 2.715345 26.73333 0.735822 27.72333 1.537606 
4.5 30.05 2.624633 26.60333 1.718847 29.55667 2.037163 
5 32.02 3.473197 28.27667 1.160704 31.6 0.843267 
5.5 33.55333 3.522504 29.09333 1.115542 33.45 1.261467 
6 38.07667 3.689679 31.07333 1.120952 32.59333 3.30155 
6.5 38.72667 3.756891 32.05333 0.300056 34.28 3.354236 
7 42.71 2.816931 35.49667 1.487425 36.23 3.917895 
7.5 44.65667 3.302822 40.62 1.88008 42.13667 0.748086 
8 51.51 3.761396 42.88 0.870689 44.48667 1.372747 
8.5 54.52667 3.960067 47.57 2.175017 48.04 0.727461 
9 57.46 0.736546 54.75 3.902461 51.64333 1.796228 
9.5 63.70667 1.808462 57.16 1.872618 55.98 2.732105 
10 68.22 3.412858 60.67333 2.223181 60.61667 2.708733 
10.5 73.16667 1.651706 64.70667 0.260832 66.53 2.58215 
11 76.28333 2.283689 69.22667 1.392276 69.69667 3.865751 
11.5 79.88333 1.037224 71.66333 2.104954 69.86333 2.530856 
12 82.11333 1.445764 73.30333 1.768738 72.86 1.998274 
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Table – 3e 
In Vitro Release Profile of Perindopril Erbumine Floating Microspheres 
 
Time 
(Hours) 
Cumulative % Drug Release 
Formulation Code 
F16 (D:P 1:4) F17 (D:P 1:1) F18 (D:P 1:2) 
Mean ±SD Mean ±SD Mean ±SD 
0.25 5.96 1.548257 10.36 2.565015 18.11 1.548257 
0.5 12.28667 0.810946 14.88667 2.389756 21.68467 1.03201 
0.75 15.46333 1.272255 22.28667 0.536128 24.13667 0.768266 
1 16.79333 1.050016 25.90667 1.300936 27.98 0.25 
1.5 18.51 0.9531 29.41667 0.478992 28.95333 1.465754 
2 19.23667 0.446132 32.24333 1.811307 30.80533 2.819593 
2.5 21.28 0.264575 36.30333 0.810267 32.81 1.253834 
3 22.67 1.045897 39.89333 0.381357 34.85 1.261943 
3.5 23.24333 1.609358 42.97 1.080879 38.1 1.992712 
4 24.49667 1.624633 44.72667 1.114286 42.04 1.775021 
4.5 26.29333 1.125093 46.79667 3.071845 45.49667 0.761993 
5 27.38667 1.26753 49.14 2.174695 47.82667 2.051008 
5.5 29.37333 1.702273 54.33 2.707342 50.22 1.84258 
6 31.19 1.751942 56.62 2.510598 52.53667 0.53799 
6.5 32.18 1.464616 59.31667 1.261837 55.4 1.481317 
7 33.66667 1.320391 63.32333 2.876549 59.25 1.036774 
7.5 35.20667 1.220341 65.94667 2.558913 60.31333 1.007588 
8 36.75333 4.032088 69.02333 1.998032 63.31333 1.620041 
8.5 40.49333 2.278296 70.51733 0.715039 66.11 0.571052 
9 44.77667 2.701672 72.72667 0.820386 67.08667 1.235084 
9.5 48.04667 2.948446 74.86 0.521632 68.80667 0.166233 
10 51.22 2.960203 78.63 0.347707 70.59667 0.956312 
10.5 55.06667 2.952581 80.37333 0.792233 73.09667 0.673226 
11 60.74 4.296894 83.7 1.160129 74.88 0.390512 
11.5 66.89333 1.017955 85.82667 0.217332 75.86333 1.025736 
12 68.58333 2.567729 86.95333 0.633193 78.05333 0.241109 
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Table – 3f 
In Vitro Release Profile of Perindopril Erbumine Floating Microspheres 
Time (Hours) 
Cumulative % Drug Release 
Formulation Code 
F19 (D:P  1:3) F20 (D:P  1:4) 
Mean ±SD Mean ±SD 
0.25 6.483333 1.304697 5.516667 0.695869 
0.5 15.14333 1.546167 12.43 1.005037 
0.75 16.85 1.313278 15.87667 0.487887 
1 20.89333 1.010412 19.68 1.253675 
1.5 23.13667 0.44658 21.80333 1.45139 
2 24.63 0.554617 24.03 0.832646 
2.5 28.55 1.655023 27.28667 0.570468 
3 29.88667 0.833627 29.45333 0.551483 
3.5 33.48667 1.209683 31.76667 1.372455 
4 35.56667 0.866333 34.46667 0.905612 
4.5 38.15 1.105848 35.48667 1.434376 
5 38.88667 2.40134 35 2.157869 
5.5 42.49 1.557915 37.38667 1.361225 
6 44.61 1.774345 39.11 1.185791 
6.5 46.42667 0.570029 41.41667 0.925869 
7 48.42333 0.46694 43.03667 0.595511 
7.5 50.92667 1.557573 44.57 1.348369 
8 54.10333 0.785133 45.40667 0.651178 
8.5 56.67667 1.558728 46.52333 0.90257 
9 58.97667 1.706878 48.84667 1.080293 
9.5 60.83667 1.600292 50.28 0.886397 
10 64.81 1.135297 53.33 2.798339 
10.5 66.81 1.731127 56.72667 1.516718 
11 69.74333 0.150444 60.35667 0.966713 
11.5 71.70667 0.285715 63.55667 2.711205 
12 73.36667 0.255016 66.84667 2.26014 
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Table 4: Percentage Yield, Particle Size, Entrapment Efficiency and Percentage 
Buoyancy. 
 
 
Formulation 
code 
Theoretical 
loading 
(%) 
Actual 
loading 
(%) 
Percentage 
yield (%) 
Particle 
size(µm) 
Entrapment 
efficiency 
(%) 
Percentage 
buoyancy 
(%) 
F1 50.00 42.05 76.27 521.3 84.10 62.06 
F2 33.33 29.43 65.54 435.0 88.29 65.30 
F3 25.00 22.89 66.15 430.0 91.58 66.07 
F4 20.00 19.15 75.16 569.0 95.79 69.62 
F5 50.00 42.99 74.00 666.0 85.98 68.66 
F6 33.33 29.43 69.12 865.2 88.29 71.72 
F7 25.00 23.36 83.56 858.0 93.45 77.91 
F8 20.00 19.19 76.84 983.0 95.79 82.77 
F9 50.00 33.17 66.80 447.8 66.35 66.54 
F10 33.33 25.75 78.08 566.6 77.25 67.01 
F11 25.00 15.88 79.95 603.6 79.43 69.20 
F12 20.00 18.69 71.52 761.3 93.45 67.85 
F13 50.00 33.64 80.12 500.2 67.28 68.07 
F14 33.33 22.89 64.28 616.0 68.69 70.00 
F15 25.00 19.62 71.36 707.4 78.50 72.83 
F16 20.00 17.28 60.05 716.6 86.44 73.58 
F17 50.00 35.51 78.60 536.7 71.02 66.66 
F18 33.33 26.16 72.56 612.0 78.51 68.51 
F19 25.00 22.89 75.76 677.0 91.56 71.48 
F20 20.00 19.15 91.58 801.0 95.75 74.33 
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Table-5 KINETICS OF IN-VITRO RELEASE FROM FLOATING MICROSPHERES OF PERINDOPRIL ERBUMINE 
 
 
Formulation 
Code 
 
Zero order Kinetics First order Kinetics Higuchi Model Korsmeyer-Peppas 
model 
Hixson Crowell 
 
R
2
 value 
 
K0(mg/h
-1
) 
 
R
2
 value 
 
K1(h
-1
) 
 
R
2
 value 
 
KH(mg/ h
-
1
) 
 
R
2
 value 
 
n value 
 
R
2
 value 
 
KHC(h
-1/3
) 
FI 0.9640 5.784 0.9799 -0.0537 0.9860 23.05 0.9823 0.5276 0.9911 -0.144 
F2 0.9606 5.262 0.9804 -0.0430 0.9894 20.93 0.9876 0.5186 0.9929 -0.122 
F3 0.9846 4.617 0.9662 -0.0314 0.9615 18.45 0.9719 0.6427 0.9841 -0.097 
F4 0.9755 4.506 0.9813 -0.0310 0.9773 18.03 0.9772 0.5818 0.9916 -0.093 
F5 0.9745 5.478 0.9035 -0.0466 0.9385 21.59 0.9422 0.5888 0.9458 -0.129 
F6 0.9474 4.606 0.9851 -0.0347 0.8824 17.88 0.9181 0.5941 0.8931 -0.100 
F7 0.9714 5.101 0.9142 -0.0399 0.9172 20.02 0.9365 0.6228 0.9419 -0.114 
F8 0.9879 4.544 0.9600 -0.0319 0.9973 18.11 0.9698 0.5765 0.9740 -0.045 
F9 0.9570 5.142 0.9326 -0.0413 0.9670 20.54 0.9732 0.5509 0.9561 -0.116 
F10 0.9700 4.857 0.9536 -0.0365 0.9619 19.30 0.9594 0.5556 0.9710 -0.106 
F11 0.9683 4.573 0.9320 -0.0327 0.9483 18.13 0.9685 0.5957 0.9553 -0.096 
F12 0.9720 4.606 0.9336 -0.0330 0.9342 18.16 0.9487 0.5992 0.9551 -0.097 
F13 0.9690 5.953 0.8775 -0.0579 0.8902 23.47 0.9223 0.7266 0.9158 -0.143 
F14 0.9359 5.038 0.8647 -0.0393 0.8261 19.33 0.8795 0.6982 0.8909 -0.113 
F15 0.9524 5.000 0.8844 -0.0387 0.8630 19.33 0.9095 0.6688 0.9114 -0.111 
F16 0.9780 6.007 0.9846 -0.0518 0.9847 24.33 0.9878 0.6302 0.9933 -0.143 
F17 0.9655 6.309 0.9722 -0.0649 0.9901 25.35 0.9905 0.5482 0.9908 -0.167 
F18 0.9575 5.330 0.9813 -0.0471 0.9814 20.92 0.9873 0.5257 0.9969 -0.128 
F19 0.9754 5.270 0.9779 -0.0416 0.9783 21.12 0.9837 0.5839 0.9883 -0.118 
F20 0.9508 4.380 0.9574 -0.0306 0.9699 17.51 0.9677 0.5066 0.9666 -0.091 
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Figure: 14 
DETERMINATION OF λ MAX OF PERINDOPRIL ERBUMINE 
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Figure: 15 
CALIBRATION OF PERINDOPRIL ERBUMINE 
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Figure 16 DSC THERMOGRAM OF DRUG AND POLYMERS 
Drug (perindopril erbumine) 
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Figure 17 
FT-IR SPECRUM OF PERINDOPRIL ERBUMINE 
FT-IR SPECRUM OF ETHYL CELLULOSE 
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FT-IR SPECRUM OF PVP K30 
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FT-IR SPECRUM OF DRUG+EC 
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FT-IR SPECRUM OF DRUG+EC+ES100 
 
 
FT-IR SPECRUM OF DRUG+EC+PVP K90 
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Figure-18 
HISTOGRAM OF PERCENTAGE ENTRAPMENT EFFICIENCY OF DIFFERENT PERINDOPRIL ERBUMINE 
FLOATING MICROSPHERES FORMULATIONS 
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Figure 19 In-vitro floating behaviour of perindopril erbumine floating microspheres 
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Figure-20 
IN-VITRO RELEASE PROFILE OF PERINDOPRIL ERBNUMINE WITH ETHYL CELLULOSE POLYMER AT DIFFERENT 
RATIOS 
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Figure-21 
IN-VITRO RELEASE PROFILE OF PERINDOPRIL ERBNUMINE WITH ETHYL CELLULOSE & HPMC  POLYMER AT 
DIFFERENT RATIOS 
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Figure-22 
IN-VITRO RELEASE PROFILE OF PERINDOPRIL ERBNUMINE WITH ETHYL CELLULOSE & PVP K30  POLYMER AT 
DIFFERENT RATIOS 
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Figure-23 
IN-VITRO RELEASE PROFILE OF PERINDOPRIL ERBNUMINE WITH ETHYL CELLULOSE & EUDRAGIT S100  POLYMER 
AT DIFFERENT RATIOS 
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Figure-24 
IN-VITRO RELEASE PROFILE OF PERINDOPRIL ERBNUMINE WITH ETHYL CELLULOSE & PVP K90  POLYMER AT 
DIFFERENT RATIOS 
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Figure-24a 
COMPARISON OF IN-VITRO RELEASE PROFILE OF FLOATING MICROSPHERES OF PERINDOPRIL ERBNUMINE WITH 
DIFFERENT POLYMERS 
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Figure-26 
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Figure-28 X-ray diffraction pattern of perindopril erbumine, polymer 
mixture (Ethyl Cellulose & HPMC) and floating microsphere 
formulation (F8) 
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Figure-29 SEM Picture o
Dissolution) 
 
                                Results & disc
f Floating Microspheres Formulati
ussion 
Page 132 
 
 
on F8 (Before 
                                                                   Results & discussion 
 
Madurai Medical College Page 133 
 
 
 
Figure-30 SEM Picture of Floating Microspheres Formulation F8 (After 
Dissolution) 
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Figure 31- IN-VIVO FLOATING BEHAVIOUR OF PERINDOPRIL ERBUMUNE FLOATING MICROSPHERES 
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SUMMARY AND CONCLUSION 
SUMMARY 
 Perindopril erbumine is preferentially absorbed in the proximal small 
intestine (narrow absorption window), the drug displays oral bioavailability 
problems in conventional dosage forms. 
 The objective of the present investigation was to develop floating microspheres 
of perindopril erbumine to achieve controlled release and prolongation of gastric 
retention time. 
 Floating microspheres were prepared by double emulsification (w/o/o) solvent 
diffusion technique using different polymers such as Ethyl cellulose,  Ethyl 
cellulose with HPMC, Ethyl cellulose with PVP K30, Ethyl cellulose with 
Eudragit S100 and Ethyl cellulose with PVP K90.  
 The yield percentage of the produced microspheres is calculated for each batch 
by dividing the whole weight of product (M) by the total expected weight of 
drug and polymer (Mo). 
 Particle size distribution was analyzed by sieving method. 
 The Entrapment efficiency of prepared microspheres is calculated by using given 
formula 
Entrapment efficiency (%) = Experimental drug content/ Theoretical drug content x 
100 
 The floating microspheres are spread over the surface of the dissolution medium 
that is agitated by a paddle rotated at 100 rpm. 
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  The microspheres that floated over the surface of the medium and those settled at 
the bottom of the jar are recovered separately. After drying, each fraction of the 
microspheres is weighed and the buoyancy of the microspheres is calculated                                
 In vivo studies were performed in Rabbits using x-ray imaging technique. The 
rabbit was exposed to x-ray imaging in the abdominal region, photographs were 
taken at 0, 4, 8 & 12 hrs after administration of microspheres. The gastric 
residence time was observed. 
 The FT-IR results showed that there was no interaction between the drug and 
polymer 
 The DSC results suggested clearly that there was no interaction between the 
drug and the polymers and the drug was existed in its unchanged form. 
 Among the different drug polymer ratios investigated 1:4 (F4, F8, F12, F16, and 
F20)    drug-polymer ratio had the maximum capacity for drug entrapment. 
Among all the formulations F8 (Ethyl cellulose +HPMC) had the better 
Entrapment efficiency (95.79%),  
 The buoyancy percentage for all batches was almost above 60%, which was 
studied for 12hrs, in 0.1M HCL without enzymes. Among all the formulations F8 
(Ethyl cellulose +HPMC) had the better in-vitro percentage buoyancy 
(82.77%), 
 The cumulative percentage drug release after 12 hr was found to 65.98% to 
86.5%.It was found that the drug release was prolonged up to 12 hrs. Among all 
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the formulations F8 (Ethyl cellulose +HPMC) had the better retardant effect 
(68.13% in 12 hours). 
 It was also observed that, increase in the polymer ratio decreased the drug release. 
So, the controlled release of drug may be attributed to the slower rate of diffusion 
of dissolution medium into the microspheres due to increased density of the 
polymer matrix at higher concentration resulted in an increased diffusion path 
length.  
 
CONCLUSION: 
 In-vitro data obtained for floating microspheres of perindopril erbumine 
showed good entrapment efficiency, good buoyancy and prolonged drug release. 
Microspheres of different size and drug content could be obtained by varying the 
formulation variables. From the results it can be concluded that the drug release 
from the floating microspheres matrix was controlled by the polymer proportion. 
Prepared formulation showed appropriate balance between buoyancy and drug 
release rate. 
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